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ABSTRACT

Noel, Brett M. Ph.D., Purdue University, December 2015. Proteogenomic Insights Into
the Nature Of Chemoresistance In Chronic Myelogenous Leukemia. Major Professor:
Laurie Parker.
Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the
formation of the Philadelphia chromosome, a reciprocal translocation of the ABL1
oncogene on chromosome 9, and the breakpoint cluster region gene (BCR) chromosome
22, resulting in the BCR-ABL oncoprotein. BCR-ABL is a constitutively active tyrosine
kinase that regulates cell growth and differentiation, leading to uncontrolled cell
proliferation by deregulating downstream signaling pathways.
A revolution in cancer treatment was ushered in with the introduction of
imatinib mesylate (Gleevec®), an ATP-competitive inhibitor specific to BCR-ABL which
traps the oncoprotein in its inactive conformation, leading to its degradation . Imatinib
validated small-molecule kinase inhibitors as promising candidates for cancer therapy.
However, a small but significant portion of CML patients is intrinsically resistant to
imatinib, and others develop resistance over time. Mutations in the kinase domain
preventing drug binding are partially responsible for resistance, but in many patients, no
mutations are present. Second-generation BCR-ABL TKIs nilotinib and dasatinib have
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been developed which inhibit BCR-ABL even in the presence of kinase domain mutations
conferring resistance to imatinib, but resistance to both second-generation tyrosine
kinase inhibitors (TKIs) has been reported. We have developed lines of K562 cells
resistant to imatinib (K562-IR), nilotinib (K562-NR), and dasatinib (K562-DR),
respectively. We used a proteogenomic approach, bridging transcriptomics with
proteomics to attempt to unravel the mechanisms underlying TKI-resistance and
identify potential biomarkers of TKI-resistance in CML. We identified significant
increased protein expression in proteins involved in cell proliferation, and a reduction of
the proteins involved in protein translation across all three TKI-resistant cell lines, and
also identified novel fusion genes present in our TKI-resistant cell lines that could
potentially serve as biomarkers of acquired resistance.
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CHAPTER 1.

1.1

INTRODUCTION

The Cell and Cancer

1.1.1 Cellular Signaling Controls Cell Functions
The cell is basis of all human life, and constantly adapts to its environment. The cell
reacts to external or internal stimuli through intricate molecular signaling pathways that
can take the form of protein-protein interactions, ligand-receptor interactions, posttranslational modifications, or protein-DNA interactions, and others, all of which can
effect downstream gene expression, allowing the cell to properly respond to stimuli. The
ability to sense and react to stimuli ensures proper cell differentiation and proliferation,
and allows the cell to undergo apoptosis before attaining deleterious properties. This
process continues to form tissues, and organs, and the cells comprising these tissues
and organs communicate through cell-cell interactions composed of molecular signals.
Molecular signaling is critical to maintain cellular homeostasis. Cells must regulate the
influx and efflux of proteins, ATP, and ions, the internal pH of the cell, and neutralize
free radicals, which can damage DNA. Cellular proliferation is also regulated by
molecular signaling events that are coordinated throughout the cell cycle. A system of
molecular checks and balances ensures that cells proliferate properly, and undergo the
process of apoptosis, or programmed cell death, if they cannot maintain the proper
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functions of that cell. Regulation of many processes at once requires integration of
many signaling inputs, and a coordinated response of outputs that allows the cell to
maintain its properties and perform its functions. While this process is unfathomably
dynamic, it is also very delicate.

1.1.2 Cell Signaling and Mutation
Genetic mutation has wide-ranging effects on the ability of the cell to sense and adapt
to its environment, and is necessary for the progress of evolution to proceed. There are
many types of mutations, which can have varying phenotypic consequences ranging
from null consequences to developmental abnormalities and organismal death. A lossof-function mutation produces an inactive gene product, and is often recessive in
diploid organisms because another copy of the gene is present and can compensate for
the loss of function[1]. A gain-of-function mutation strengthens the effect of the gene
product, and is known as an activating mutation[2]. Dominant-negative mutations are
mutations that cause the mutant gene product to have an antagonistic effect on the
wild-type gene. Dominant-negative mutations have been implicated in oncogenesis,
such as the mutations found in the tumor-suppressing protein p53[3]. Mutations in p53
have been found in many tumors, and inhibition of p53 function has been shown to
increase invasiveness, metastasis, and overall tumor growth by changing the activation
of signaling networks in the cell[4].
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Genetic mutations can arise in many ways, such as errors in DNA replication, or through
external environmental factors such as exposure to UV light from the sun causing DNA
damage[1, 2, 4-7]. A frameshift mutation arises from an insertion or deletion of a
nucleotide or nucleotides in the gene encoding a protein, and changes the ensuing
amino acid sequence by shifting the codon sequence produced, leading to dramatic
changes in the composition of the protein eventually translated from the mRNA
produced by the gene[8]. A nonsense mutation occurs when a mutation in a gene
encodes for a premature stop codon, leading to the translation of a truncated protein[9].
Missense mutations occur when a point mutation a gene changes the codon produced,
and the resulting amino acid sequence is altered only at the codon affected by the
missense mutation[5, 10]. There are also neutral and silent mutations. Neutral
mutations occur when alteration of the genetic code encodes for a chemically similar
amino acid, such as the substitution of an arginine residue for a lysine residue[11]. A
silent mutation refers to a mutation producing the same amino acid, despite the
presence of a mutated nucleotide residue[12].

The mutation of an amino acid residue can disrupt the balance of complex molecular
signaling networks by encoding for an inactive protein, an overactive protein, or a
protein that otherwise alters the ability of the cell to sense and react to its environment
such as the ability of the protein to bind other proteins or DNA. Mutation can also occur
at the gene level, producing mutated proteins with the ability to effect cell growth.
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Rearrangements of whole chromosomes can even occur, leading to novel genetic
products. The generation of a novel gene due to the juxtaposition of two genes normally
found in distant positions on the same chromosome or entirely different chromosomes
is known as chromosomal translocation[13-19], which can result in genetic products
that can be translated into mutant fusion proteins if open reading frames are preserved.
Conversely, a situation that results in the deletion of a gene is known as an interstitial
deletion[20], whereas the reversal of gene orientation is known as an inversion[21].
Mutations at the chromosomal level are equally capable of leading to disease
pathologies as mutations at the amino acid level, particularly when fusion proteins are
produced or critical genes are deleted. The consequences of mutation are variable, but
many diseases arise from mutations altering the ability of genes important in molecular
signaling to maintain homeostasis.

1.1.3 Genetic Mutation and Cancer
The term cancer refers to a collection of diseases characterized by uncontrolled cellular
proliferation, resistance to apoptosis, evasion of growth suppression, increased
angiogenesis, enabling replicative immortality, invasion and metastasis, reprograming of
energy metabolism, and the ability to avoid immune detection[22]. The underlying
cause of cancer is genomic instability, which compromises the ability of the cell to sense
and properly react to its environment. Mutation of genes involved in the regulation of a
variety of cellular processes, such as cell cycle regulation, cell proliferation, or DNA
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damage response can cause oncogenesis[22]. The mutation of one protein in a complex
signaling system can have wide-ranging effects that drive unchecked proliferation. A
notable example of this is the mutation of the protein B-RAF, which occurs in about 66%
of human melanomas. The protein RAS binds to a serine-threonine kinase RAF,
activating RAF. RAF phosphorylates MEK, which phosphorylates a MAP kinase, which
phosphorylates several transcription factors that activate transcription of genes critical
to driving cell proliferation. One of these genes is the kinase EphA2, which
phosphorylates p120RasGAP, which in turn downregulates wild-type RAS as a negative
feedback mechanism to control the rate of cell proliferation[23-25]. However, mutant
RAS is not downregulated, and the signaling cascade can proceed unchecked. Many
other targets of the MAPK pathway are also affected, including repression of apoptotic
signals, cell-cycle checkpoints, and cell division machinery. Despite the fact that cancer
is caused by genomic instability, there are currently no methods to directly target the
genetic instability underlying cancer progression, we must overcome this limitation by
targeting the protein products of genomic instability.

1.1.4 Therapeutic Strategies in Cancer
Initial attempts to treat cancers using chemicals were considered largely successful at
the time. The first use of chemicals in cancer therapy (chemotherapy) was in 1942,
when Louis Goodman and Alfred Gilman used nitrogen mustards; a derivative of the
mustard gas used a chemical warfare agent in World War I, to induce the regression of a
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tumor in a patient being treated for non-Hodgkins lymphoma[26]. This was the first
demonstration that cancer could be treated with pharmacological agents. Sidney Farber
expanded on the discoveries of Goodman and Gilman in 1948, when he used the
antifolate derivatives aminopterin and methotrexate to treat children with acute
lymphoblastic leukemia (ALL)[27]. Because ALL is a disease of white blood cells, it is
possible to directly measure the effect of chemotherapy by simply drawing blood and
counting the depletion of cells over the course of treatment, and his highly controversial
report in the New England Journal of Medicine piqued interest in the development of
new pharmacological agents as anti-cancer therapies. At the time, little was known
about the molecular biology of cancer. Accordingly, many cancer treatments developed
then would be deemed barbaric by today’s standards due to the fact that none of the
treatments selectively targeted cancer cells. Other strategies for treating patients with
cancer were based on the rationale that by developing treatments biased toward rapidly
proliferating cells, one could kill all cancer cells before killing the patient. The evolution
of cancer treatments progressed with the realization that disruption of the
incorporation of nucelosides into a new strand of DNA would cause cells to undergo
apoptosis, and the drug 6-mercaptopurine, which eventually became incorporated into
DNA as a 6-thioguanine nucleotide, was discovered to be highly effective at treating
leukemias[28]. With new therapies came undesirable side effects, and new forms of
therapy targeting diverse aspects of cancer hallmarks were conceived. Vinca alkaloids
were next developed, which inhibit microtubule polymerization and consequently
inhibit mitosis leading to cell death[29]. Vinca alkaloids were followed by taxanes such
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as paclitaxel, which inhibit the breakdown of microtubules leading to inhibition of cell
division, topoisomerase I inhibitors such as camptothecin, which prevents DNA religation during DNA synthesis leading to apoptosis, platinum-containing cancer drugs
such as cisplatin, which induces irreparable DNA damage by cross-linking to DNA leading
to apoptosis, and alkylating agents such as cyclophosphamide, which inhibit DNA
synthesis by cross-linking DNA strands leading to apoptosis[29-33]. All of these therapies
were effective to an extent, but the side effects of untargeted therapies, such as fatigue,
loss of appetite, sexual dysfunction, neuropathy, and organ damage were devastating
for many cancer patients. Better therapies were needed to directly treat the many
different causes of cancer.

In the 1990’s it was recognized that the growth of some breast cancers was partially
dependent on the hormone estrogen. Estrogen binds to a receptor (estrogen receptor,
ER) on breast cells and activates an intracellular molecular signaling cascade promoting
breast cancer cell proliferation. To combat this critical signaling event, Tamoxifen, a drug
developed in the 1960’s as a potential emergency contraceptive was repurposed as an
anti-estrogen compound. Tamoxifen is a prodrug that is metabolized by cytochrome
P450 isoforms CYP2D6 and CYP3A4 in the liver to yield the active metabolites 4hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen, which bind the ER on breast
cancer cells with high affinity, blocking estrogen from binding to its receptor. The ER/4hydroxytamoxifen complex also recruits repressors of cell proliferation, and modulates
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the expression of genes driving cell proliferation[34]. The introduction of a molecule
that blocked molecular signaling as a breast cancer treatment was a crucial step toward
recognizing the need for targeted therapies in cancer treatment. An understanding of
the underlying molecular machinery driving cancer progression was sorely lacking, and
without a fundamental understanding of the driving forces behind cell proliferation, the
development of targeted therapies was inefficient and ineffective.

1.1.5 Molecular Signaling and Cancer
Cancer is a disease that is characterized by uncontrolled cell proliferation, and the
proliferation of healthy cells is tightly controlled by a system of checks and balances.
Highly intertwined molecular signaling networks communicate by receiving and
integrating signals from extracellular growth factors, cell-cell contact, and other
intracellular signaling networks to regulate cell proliferation, protein synthesis, DNA
synthesis, energy metabolism, and apoptosis[2, 24, 25, 35-38]. Disruption of these
signals can cause an imbalance in the downstream signaling events, which are reliant on
the information obtained from upstream signals. An imbalance in a signaling network
propagates throughout the network and cells that cannot correct for imbalances can
attain the characteristic properties of cancer, such as unregulated cell growth. A
prominent molecular signaling mechanism is the enzyme-catalyzed transfer of a
phosphate group from the active site of an enzyme known as a kinase to the desired
target on a protein substrate[39]. Phosphorylation is a reversible process used to
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control cell differentiation, proliferation, and apoptosis, and the 520 kinases make up
approximately 2% of the human genome. There are two major classes of protein kinases,
those that preferentially phosphorylate serine and threonine residues, and those that
preferentially phosphorylate tyrosine residues. Serine/threonine kinases comprise
approximately 80% of the protein kinases in the human genome, and although tyrosine
kinases comprise about 20% of human protein kinases, tyrosine residues represent only
about 1.8% of the phosphorylated residues in the human body[40]. Despite the
dramatic difference in abundance, tyrosine kinases are tremendously important in cell
signaling.

Tyrosine kinases are composed of two different sub-classes of protein kinases. Nonreceptor tyrosine kinases (NRTK) which are free to roam about the intracellular space of
the cell, and receptor tyrosine kinases (RTK), membrane-bound kinases activated by a
ligand binding to the extracellular surface of the cell, which transduce extracellular
signals into intracellular signals.[40-43]. Most RTKs exist as monomeric subunits, but
others consist of multimeric units that work together to convert extracellular signals to
intracellular signals. For example, the insulin receptor (IR) is a tyrosine kinase that plays
a critical role in the regulation of glucose homeostasis. During transcription, alternative
splicing leads to two isoforms of the gene, IR-A and IR-B. Downstream post-translational
modification of the IR-A and IR-B protein products leads to α and β subunits, which can
form homodimers or heterodimers to produce the insulin receptor complex. The IR
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complex can bind insulin, Insulin-like Growth Factor I (IGF-I), and Insulin-like Growth
Factor II (IGF-II). Binding of the ligand causes a conformational change in the dimer,
resulting in autophosphorylation of the intracellular tyrosine residues on the β chain of
the tyrosine kinase domain[44]. Phosphorylation of the tyrosine residues recruits
adaptor proteins such as insulin receptor substrate (IRS) proteins, SH2-B domains, and
phosphatases such as PTP1B to the tyrosine kinase domain, which regulate the
downstream processes required to maintain glucose homeostasis[45]. In contrast,
NRTKs are unbound and are free to move around the intracellular space freely. A wellknown example of a NRTK is Ableson protein tyrosine kinase 1, also known as c-Abl. cAbl has many diverse functions in the cell, such as cytoskeleton remodeling in response
to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy,
DNA damage response and apoptosis. c-Abl is typically found in the cytoplasm, but can
be shuttled into the nucleus through protein-protein interaction with 14-3-3 scaffold
proteins, and upon nuclear translocation, c-Abl is able to bind DNA and is involved in the
DNA damage response, and activation of pro-apoptotic pathways if the damage to DNA
is too much for the cell to survive[46].

Tyrosine kinases are ubiquitously expressed in many cell types, and have been
prominently implicated in the progression of cancer. Janus kinase 2 (JAK2) is a NRTK in
the cytokine type II receptor family that is critical to IL-3 receptor signaling, driving
proliferation, differentiation, and apoptosis. JAK2 phosphorylates the STAT transcription
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factors in the cytoplasm, and consequently the STAT transcription factors translocate to
the nucleus and activate transcription of genes such as SOCS3, a negative regulator of
RasGRP. RasGRP is a negative regulator of RAS, so the JAK2/STAT pathway indirectly
activates the RAS pathway[47]. In several myeloproliferative disorders, JAK2 contains an
activating mutation where the valine at the 617th amino acid position is mutated to a
phenylalanine (V617F). This mutation allows for constitutive activation of JAK2 kinase
activity, which drives unregulated cell proliferation[48]. Possibly the most famous
example of tyrosine kinase involvement in cancer progression is the fusion protein BCRABL, produced by the chromosomal translocation of the breakpoint cluster region gene
on chromosome 22 with the c-Abl tyrosine kinase on chromosome 9. The resulting
chromosome is known as the Philadelphia Chromosome, and is found in 95% of all
chronic myelogenous leukemia patients. The resulting fusion protein replaces exon 1
from the c-Abl gene with the BCR gene, resulting in a constitutively active form of c-Abl.
The BCR-ABL oncoprotein is then free to drive unregulated cell proliferation through
activation of the RAS/MAPK, JAK2, PI3K, and CRKL pathways[13, 15-17, 19, 46, 49-51].
The ability of tyrosine kinases to disrupt many signaling networks at once makes them
prime candidates for pharmacological inhibition, and the development of specific
tyrosine kinase inhibitors marked a turning point in the ability of physicians to treat
cancer patients.
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1.1.6 Chronic Myelogenous Leukemia Pathology
Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the
formation of the Philadelphia Chromosome, a reciprocal translocation of the 3’ end of
the gene encoding the ABL1 tyrosine kinase on chromosome 9, and the 5’ region of the
breakpoint cluster region gene (BCR) chromosome 22, resulting in the BCR-ABL
oncogene. The protein encoded by BCR-ABL is a constitutively active 210 kDa tyrosine
kinase that regulates cell growth and differentiation, leading to uncontrolled cell
proliferation by deregulating downstream signaling pathways[19, 46, 52]. The structure
of the fusion protein lends insight into its constitutive nature. While the exon encoding
the tyrosine kinase activity of ABL remains intact, the loss of an N-terminal
myristoylation site removes an ABL autoinhibition site, resulting in increased kinase
activity and unregulated propagation of downstream cell proliferation signals. Antisense
oligonucleotides and knockout mouse models have demonstrated that BCR-ABL is a
critical mutation on the path to develop CML, and thus represents an excellent target
for innovative treatment strategies[53].

The BCR-ABL fusion protein drives oncogenesis through multiple prominent signaling
pathways. BCR-ABL activates the JAK/STAT pathway through activation of STAT5, a
transcription factor necessary for CML development. STAT5 is a known substrate of
JAK2, and knockout of STAT5 prior to BCR-ABL mediated CML induction prevented the
development of CML in a mouse model. Interestingly, knockout of JAK2 had no effect on
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the development and maintenance of CML, suggesting BCR-ABL is capable of activating
STAT5 directly[50]. BCR-ABL also activates the Phosphoinositide 3-Kinase (PI3K) pathway
through the activation of GRB2/GAB2 and CBL adaptor proteins, and pharmacological
inhibition of PI3K signaling incudes apoptosis in primary CML cells[54]. However, BCRABL is perhaps most commonly associated with the activation of Src-family kinases,
kinases prominently involved in cell growth, differentiation, and motility. The SRC-family
kinases HCK and LYN are strongly activated in the presence of BCR-ABL and along with
FYN, another SRC-family kinase, are required for BCR-ABL mediated CML induction[42,
55-58].
BCR-ABL-mediated CML progression is not mechanistically limited to deregulated cell
proliferation, but BCR-ABL also inactivates apoptosis pathways in a two-pronged
manner. BCR-ABL mediated STAT5 regulation increases the expression of BCL-XL and
BCL-2, anti-apoptotic genes that inhibit apoptosis by inhibiting cytochrome C release
from the mitochondria, preventing caspase activation and thus inhibiting apoptosis[15].
Constitutively active BCR-ABL also activates the PI3K/AKT pathway, which
phosphorylates the pro-apoptotic BCL2-associated Death promoter (BAD), promoting
it’s association with 14-3-3 scaffolding proteins, sequestering BAD in the cytoplasm and
preventing BAD from activating pro-apoptotic genes in the nucleus[54, 59, 60].
The progression of CML occurs in three phases. Most patients are diagnosed in the
chronic phase (CML-CP), in which most patients experience no symptoms and a
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quiescent population of hematopoietic stem cells, termed Leukemic Stem Cells (LSCs),
lies dormant in the bone marrow. Although it is yet unknown what molecular events
lead quiescent cells to gain self-renewal capabilities and begin proliferating
uncontrollably, CML can then progress through an accelerated phase (CML-AP), or
directly to blast phase (CML-BP)[52, 61]. CML-AP is defined as the presence of any of the
following symptoms: 10-19% myeloblasts present in the blood or bone marrow, platelet
count <100,000 related to therapy, platelet count >1,000,000 and unresponsive to
therapy, >20% basophils in the blood or bone marrow, cytogentic evolution unrelated to
the presence of the Philadelphia Chromosome, increased splenogamy or white blood
cell count and unresponsiveness to therapy. Accelerated phase signals an imminent
progression to blast-phase, and an increased likelihood of drug resistance. Blast phase is
characterized by rapid cell proliferation brought on by inhibition of tumor suppressor
proteins, genomic instability, and shortened telomeres, resulting in >20% myeloblasts or
lymphoblasts in the blood or bone marrow, large clusters of blasts in the biopsy, and the
development of chloroma (a solid focus of tumor outside the bone marrow). Once a
patient reaches blast phase, prognosis is bleak and the patient generally has a short
time to live. It is critical to diagnose and treat CML patients before blast phase is
initiated[62, 63].
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1.1.7 Treatment of CML Using Tyrosine Kinase Inhibitors (TKIs)
Prior to the introduction of imatinib, CML was treated with a combination of cytarabine
and interferon-α therapy, or radiation therapy followed by allogenic stem cell
transplantation (the transfer of stem cells from a healthy donor to the patient after
radiation or chemotherapy). These treatment options were moderately effective, with
the median 8-year survival rate between 42-65% from 1983-2000[64].
The introduction of imatinib mesylate (Gleevec®) changed everything. Imatinib inhibits
BCR-ABL by binding its kinase domain and trapping BCR-ABL in an inactive conformation,
leading to its degradation and subsequent apoptosis of the cell. With a 7-year overall
survival rate of 86% and an event free survival rate of 81%, imatinib was a huge success,
and demonstrated that small molecule ATP-competitive inhibitors could be highly
effective cancer treatments. Since then, TKIs have been approved for BTK, ALK, VEGFR,
FGFR, KIT, SRC-family kinase, JAK, among other targets, however none have been as
successful as imatinib. For many CML patients, a daily dose of imatinib transformed a
deadly disease into a manageable condition, as BCR-ABL is the product of a fusion gene
found only in cancer cells making it a highly specific target for a small molecule inhibitor.
However, approximately 4% of CML patients are intrinsically resistant to imatinib, and
15-25% develop resistance to imatinib over time[52].
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Over 100 BCR-ABL point mutations have been identified, accounting for approximately
70% of acquired resistance to imatinib[65]. Many of these mutations prevent the
binding of imatinib in the ATP-binding pocket of BCR-ABL, leading to imatinib resistance.
Second-generation BCR-ABL TKIs nilotinib and dasatinib have been developed which
inhibit BCR-ABL even in the presence of several kinase domain mutations conferring
resistance to imatinib, but resistance to both second-generation TKIs has been
reported[66].

1.2

Imatinib, Nilotinib, and Dasatinib
1.2.1 Imatinib

Imatinib, originally termed STI571, is a methylpiperazine derivative that was developed
by Novartis in the early 1990’s. In collaboration with Dr. Brian Druker, imatinib entered
clinical trials and demonstrated remarkable efficacy in inducing apoptosis in CML cells.
Imatinib works by outcompeting ATP to bind the ATP-binding pocket of BCR-ABL when
in an inactive conformation, inhibiting its catalytic activity and driving apoptosis by
inhibiting downstream signaling pathways necessary for cell proliferation. Imatinib
inhibits BCR-ABL with high specificity, targeting only c-KIT and PDGFRα and PDGFRβ[67].
Because BCR-ABL is present in almost all CML cells, imatinib is an ideal treatment option
for patients with CML. In June 1998, Dr. Brian Druker and colleagues initiated a phase I
clinical trial in collaboration with Novartis deemed International Randomized Study of
Interferon versus STI571 (IRIS) designed to assess the safety and efficacy of imatinib in
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human patients who had failed interferon-α therapy. The results were striking. At 18
months, the rates of Complete Cytogenic Response (CCyR, defined as 0% Ph+ cells) were
76% in the imatinib group compared to only 15% in the group treated with a
combination of interferon-α and cytarabine; at 60 months 97% of patients treated with
imatinib achieved a CCyR[68]. At 18 months 100% of patients who achieved a Major
Molecular Response (MMR; defined as a reduction in levels of BCR-ABL transcript to ≤
0.1% of the average level of BCR-ABL transcript in 30 untreated CP-CML patients)
remained in chronic phase, not progressing to accelerated phase or blast phase. Despite
the success of imatinib, 15-25% of patients are either intrinsically resistant to imatinib or
acquire resistance over time. BCR-ABL kinase domain mutations are a common
mechanism conferring resistance to imatinib. Over 50 kinase domain mutations have
been identified, many of which prevent the binding of imatinib to the kinase
domain[69]. To combat imatinib resistance second-generation tyrosine kinase inhibitors
have been developed, which inhibit several variants of mutant BCR-ABL.

1.2.2 Nilotinib
Nilotinib is a second-generation BCR-ABL inhibitor that inhibits most BCR-ABL mutants
with the exception of the T315I, Y253H, E255V/K, and F359V mutations, which confer
moderate resistance to imatinib. Nilotinib is more selective than imatinib, and binds
BCR-ABL in imatinib-sensitive CML 20-50 times more tightly than imatinib, and 3-7 times
more tightly in imatinib-resistant CML[70, 71]. In a phase II clinical trial of imatinib-
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resistant patients, 46% of patients achieved a CCyR, and 56% achieved a MMR. At 24
months there was an 87% overall survival rate, with a 64% event-free survival
observed[70, 72]. As with imatinib, patients eventually become resistant to nilotinib,
and there are limited options to combat nilotinib resistance[73].

1.2.3 Dasatinib
Dasatinib is an ATP competitive TKI with dual activity against both BCR-ABL and SRCfamily kinases, specifically SRC, LCK, LYN, YES, FYN, and FRK. Dasatinib inhibits BCR-ABL
more potently than nilotinib or imatinib and its activity against the SRC- family kinases,
which have been implicated in TKI resistance, make it an advantageous treatment
option for patients resistant to both imatinib and nilotinib[74-76]. In a phase II clinical
trial of imatinib-resistant or imatinib-intolerant CML patients, dasatinib induced a CCyR
in 53% of patients at 24 months[77]. Although dasatinib inhibits BCR-ABL more potently
than nilotinib and imatinib, it does not effectively inhibit BCR-ABL containing the T315I,
E255K/G, F317L, and Q252H mutations, and dasatinib is associated with the
development of further mutations in the kinase domain, which may result in CML
resistance to all currently FDA-approved TKIs[13, 74-76, 78-80]. Despite the success of
first- and second-generation TKIs, there is clearly a need to develop third-generation
TKIs that effectively inhibit TKI-resistant BCR-ABL mutations, and explore alternative
avenues conferring resistance.
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1.2.4 Next-Generation CML Treatment
There is an unmet need to effectively inhibit BCR-ABL mutants resistant to first-and
second-generation TKIs. The most notorious mutation commonly found in patients
resistant to imatinib, nilotinib, and dasatinib is the T315I mutation, also known as the
gatekeeper mutation. The T315I mutation is significant because it removes a critical
oxygen residue necessary for first- and second-generation TKIs to bind to the kinase
domain of BCR-ABL and effectively inhibit its kinase activity. Several experimental
compounds have been proposed to meet this need, and are in varying stages of
development.

Ponatinib is a novel tyrosine kinase inhibitor that is designed to inhibit the BCR-ABL
T315I mutation, and was approved to treat patients with CP-CML, AP-CML, or BP-CML,
as well as Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) in the United States and
countries residing in the European Union. A phase II study of ponatinib yielded major
cytogenic response in over half of adults with CP-CML, and a major hematological
response in 50% of adults with BP-CML, and 34% of patients with Ph+ ALL, regardless of
the presence or absence of the T315I mutation[81]. However, serious side effects such
as vascular occlusion, heart failure, and hepatotoxicity have been observed in patients
treated with ponatinib. Although ponatinib is a promising therapeutic option for
patients resistant to other TKIs, it remains to be seen if patients will develop resistance
due to other factors.
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1.2.5 Acquired Resistance Due to Compensatory Signaling Pathway Activation
A commonly cited mechanism of resistance to imatinib and nilotinib is the overactivation of compensatory proliferative signaling pathways that allow CML cells to
evade cell death. BCR-ABL activates several prominent signaling pathways, such as the
SRC- signaling pathway, which includes LYN, a member of the SRC-family kinases.
Knockdown of LYN using antisense RNA has restored imatinib and nilotinib sensitivity in
vitro[15, 58, 82], however, dasatinib inhibits SRC-family kinase activity and patients
lacking the T315I mutation still develop resistance to dasatinib[83], suggesting that the
SRC-family kinase signaling pathway is not the only pathway compensating for BCR-ABL
inhibition. In fact, constitutive ERK2 activation has been identified as a mechanism of de
novo resistance to imatinib[84], and PI3K/AKT activation has also been described as a
mechanism underlying BCR-ABL independent acquired imatinib resistance[54]. The
study of BCR-ABL independent compensatory signaling pathway activation represents a
promising therapeutic avenue, as pharmacological inhibition of these signaling
pathways could be an effective strategy to mitigate BCR-ABL independent TKI-resistance.

1.2.6 Altered Expression of Drug Influx and Efflux Channels
The success of BCR-ABL inhibition is dependent upon the intracellular concentration of
the inhibitor, and alteration of the expression of influx and efflux pumps can affect the
internalization and accumulation of small-molecule inhibitors. Several studies have
demonstrated the upregulation of the efflux pump multidrug-resistance gene (MDR-1)
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and its translational product P-glycoprotein (PgP) in acquired resistance to imatinib.
RNAi-mediated knockdown of PgP restored sensitivity to imatinib and increased
intracellular concentrations of imatinib in K562 cells in-vitro, and pharmacological
inhibition of PgP yielded similar results[85, 86]. In the other direction, other studies
have demonstrated downregulation of influx pumps correlating with imatinib
resistance. The best studied of these transporters is OCT1, an organic cation transporter
responsible for transporting imatinib into the cell. Pharmacological inhibition of OCT1
resulted in reduction of imatinib uptake in CML cells, but the results of the study did not
establish reduced OCT1 expression as a direct cause of imatinib resistance[87].
Subsequent studies have linked low OCT1 expression with reduced response to imatinib
compared to patients that achieved a CCyR at 10 months following the onset of imatinib
therapy[88], and patients with low expression of OCT1 receiving high doses of imatinib
had much better rates of CCyR, MMR, and PFS than those with low expression of OCT1
receiving a standard dose of imatinib. Interestingly, patients with high expression of
OCT1 responded to either dosage equally well. Taken together, the expression of drug
influx and efflux transporters is a critical factor determining a patient’s sensitivity to TKI
therapy. There are many factors contributing to TKI-resistance. In this thesis we describe
the use of transcriptomics and proteomics to identify potential mechanisms mediating
TKI-resistance in a model of acquired resistance to imatinib, nilotinib, and dasatinib,
respectively.
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CHAPTER 2. IDENTIFICATION OF TRANSCRIPTOMIC DIFFERENCES BETWEEN WILDTYPE CML CELLS AND CML CELLS RESISTANT TO TYROSINE KINASE INHIBITORS

2.1

Introduction

Despite the success of frontline CML treatments such as imatinib, 15-25% of CML
patients will eventually develop resistance to therapy. In many cases, the roots of
resistance can be traced to mutations in the kinase domain of BCR-ABL, preventing
imatinib from binding to the ATP-binding pocket and inhibiting the catalytic activity of
the kinase. However, approximately 30% of patients that develop resistance to imatinib
do not exhibit any mutations preventing imatinib binding. Various explanations for BCRABL independent resistance have been proposed, such as the overexpression of BCRABL[49], compensatory signaling pathway activation[15, 82, 84, 89], downregulation of
influx pumps[90], and upregulation of efflux pumps[18], but further study is required to
identify potential biomarkers of TKI-resistance and novel mechanisms of resistance.
Every CML patient has a unique biological response to any chemotherapy, and it is
currently impossible to predict which TKI will most effectively inhibit BCR-ABL activity in
an individual patient. Further, the current gold standard to measure the efficacy of a TKI
in a CML patient is to measure BCR-ABL transcript level approximately 90 days after the
onset of treatment. A goal in the Parker lab is to design novel peptide substrates
capable of accurately reporting the kinase activity of a particular target. By measuring
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the ability of each TKI to inhibit kinase activity, physicians will be able to make a more
informed decision regarding TKI treatments on a patient-by-patient basis. Evidence
asuggests that a 50% reduction of BCR-ABL activity at 28 days is equally predictive of
treatment efficacy as measurement of BCR-ABL transcript levels at 90 days[91], and the
development of a reliable method to test treatment efficacy based on the measurement
of BCR-ABL activity would potentially improve patient survival rate and reduce the cost
of therapy.

The Parker lab has developed a set of TKI-resistant CML cell lines based on the K562
immortalized myeloid cell line containing the BCR-ABL fusion protein, with the goal of
elucidating novel biomarkers of drug resistance. To our knowledge no study has
examined a cell line model of acquired TKI-resistance using next-generation sequencing.
Here we describe the use of RNA sequencing (RNA-seq) to profile the transcriptomic
differences between the wild type K562 CML cell line, and cell lines with evolved
resistance to the TKIs imatinib, nilotinib, and dasatinib. The goal of this study is to
identify potential biomarkers of acquired resistance to TKI-treatment in vitro, that may
be able to be used to monitor resistance development in patient cells and/or suggest
alternative avenues of therapy in response to TKI-resistance.
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2.2

RNA-seq Profile of TKI-resistant K562 Cells
2.2.1 Materials and Methods

Generation of TKI-resistant Cell Lines. Dr. Steven Ouellette generated cells. K562 cells
were purchased from ATCC and grown in Isocove’s Modified Dulbecco’s Media (IMDM)
supplemented with 10% Fetal Bovine Serum (FBS) and 0.1% penicillin/streptomycin
antibiotics in a humidified atmosphere maintained at 37°C and 5% CO2. The cells were
then divided into four groups, one treated with imatinib, one treated with nilotinib, and
one treated with dasatinib, and one supplemented with 1:1,000 DMSO. Over the course
of 90 days, the cells were incubated with escalating doses of TKI and gradually acquired
resistance to the TKI in which they were incubated. The resulting cell lines were termed
K562-IR (which is maintained in IMDM supplemented with 1μM imatinib), K562-NR
(which is maintained in IMDM supplemented with 10nM nilotinib), and K562-DR (which
is maintained in IMDM supplemented with 1nM dasatinib). Each cell line was split into
three 10 cm tissue culture plates and passaged twice. When the density of the cells
reached ~7.5x105 cells/mL media the cells were harvested and total RNA was isolated
using an RNEasy kit from Qiagen. The RNA was then submitted to the University of
Minnesota Genomic Core for RNA-seq analysis on an Illumina HiSeq 2500 sequencer
using rapid mode with 50 base pair reads, and a total of 10 million reads per lane.

Differential Expression Testing. The resulting RNA-seq data were analyzed using the
Galaxy platform from the University of Minnesota Supercomputing Institute. To
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compute differential gene expression between conditions, the raw data were first
groomed to remove adapter bases using FASTQ Groomer[92], and then aligned to the
Human hg19 canonical reference genome using Tophat2[93]. Differential expression
testing between the wild type K562 cells and K562-IR, K562-NR, and K562-DR cells,
respectively, was computed using Cuffdiff, a transcript computation program available
as a package through Cufflinks[94].

Novel Fusion Transcript Detection. After the raw RNA-seq data were aligned to the
Human hg19_canonical reference genome using Tophat2, novel fusion transcripts were
detected using DeFuse, as software package used to detect fusion transcripts from
paired-end RNA-seq data[95].

Growth Inhibition Assay. K562, K562-IR, K562-NR, and K562-DR cells were transfected
with 100nM of AXL siRNA (Cell Signaling #6263), 100nM ACP5 siRNA (Life Technologies
#10032), or 100nM of CYP2S1 siRNA (Life Technologies #113728), respectively using a
Neon Transfection system (Thermo Fisher Scientific) and incubated at 37°C in a 5% CO2
humidified atmosphere. The cells were seeded at 10,000 cells per well in 96-well plates
and dosed with the indicated TKI concentrations or vehicle control (0.1% DMSO) 24
hours after transfection. The remaining cells were reserved for Western blot analysis.
Plates were incubated for two days at 37°C in a 5% CO2 humidified atmosphere.
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Following incubation, XTT reagent (ATCC) was added according to manufacturer’s
protocol and plates were incubated at 37°C in a 5% CO2 humidified atmosphere for 3
hours. Specific absorbance was read on a Biotek Synergy4 plate reader at 475 nm and
non-specific absorbance read at 660 nm. Absorbance values at 660 nm were subtracted
from 475 nm absorbance values before further data processing. To generate IC50
values, data were plotted in GraphPad Prism and curves were fit using non-linear fourparameter slope.

Western Blot Analysis. Cells were treated as described and pelleted by centrifugation.
Media was removed, and cells were washed in ice cold PBS. After washing, lysis buffer
(PhosphoSafe Extraction Buffer supplemented with 4 mM EDTA and Complete protease
inhibitor (Roche)) was added to the cell pellet and cells were incubated on ice for 30
minutes. Cell pellets were vortexed, then centrifuged at 4° C for 20 minutes to remove
insoluble cellular debris and lysate was assayed for protein content. 100 μg of protein
was mixed with Laemmli protein gel loading buffer (BioRad) and incubated at 95° C for 5
minutes. Lysate were loaded onto a 10% Mini-Protean TGS gel 59 59 (BioRad) and
separated at constant 150 V for 1 hour. Proteins were transferred to a PVDF membrane
(Millipore) and blocked with 5% BSA in TBST (tris-buffered saline supplemented
supplemented with 0.05% Tween-20). Primary antibodies (AXL (Cell Signaling, #8661),
ACP5 (Sigma Aldrich SAB1401003), CYP2S1 (Novus Biologicals NBP2-32697,), GAPDH
(Sigma Aldrich G8795) diluted 1:1000 in 5% BSA + TBST) were incubated with membrane
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overnight at 4° C. Following 3 x 5 minute washes with TBST, the membrane was
incubated with donkey anti-rabbit tagged with IRDye 800 or donkey anti-mouse tagged
with IRDye 680(1:5000 in TBST) for 1 hours at room temperature. After 3 x 5 minute
washes with TBST, the membrane was developed on a LICOR Odyssey infrared scanner.

2.2.2 Analysis of RNA-seq Results
2.2.3 Differential Expression Between K562 and K562-IR Cell Lines
The use of next-generation sequencing has been a powerful research tool to identify
difference in gene expression in a variety of pathologies and developmental stages[9698]. RNA-seq is a highly quantitative method to measure absolute transcript levels
across samples without the need to normalize data to a set of standards, and the
incredible sensitivity allows for a theoretical measurement of all transcripts present in a
population of cells. We aimed to identify differences in transcription between wild type
K562 cells and K562-IR cells in order to identify biomarkers for resistance, and
potentially explain mechanisms of resistance to imatinib treatment. After analysis using
Cuffdiff, we identified fifty-eight genes that were differentially expressed at a significant
level (p<0.05), and had an absolute log2 fold change of >1, listed in Table 1 below.
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Table 1. K562-IR genes found to have significant (p>0.05) differential expression with
respect to parental K562 cells determined by RNA-seq. Differential expression was
analyzed using Cufflinks on the Galaxy platform. Fold change is expressed in terms of
log2.

Gene

Fold Change (log2)

p-value

Function

SIGLEC6

-4.37

1.00E-04

FCGRT

-3.292

5.00E-05

PALM3
RASGRP4
CD33

-3.184
-2.967
-2.589

5.00E-05
5.00E-05
5.00E-05

TLE2

-2.527

5.00E-05

ZNF433
B3GNT8
PALM
CD320

-2.288
-1.78
-1.455
-1.344

5.00E-05
2.25E-03
5.00E-05
5.00E-05

NFIX

-1.303

5.00E-05

RAB3A
C19orf51
PPP1R14A
DLL3
CD37
CFD
BRSK1
AURKC
TUBB4A

-1.28
-1.222
-1.209
-1.176
-1.17
-1.17
-1.151
-1.144
-1.137

1.50E-04
5.00E-05
5.00E-05
3.45E-03
5.00E-05
5.00E-05
2.00E-04
1.28E-02
5.00E-05

TYROBP

-1.071

6.10E-03

FUZ

-1.022

8.60E-03

JUNB

1

5.00E-05

other
transmembrane
receptor
other
other
other
transcription
regulator
other
enzyme
other
other
transcription
regulator
enzyme
other
phosphatase
other
other
peptidase
kinase
kinase
other
transmembrane
receptor
other
transcription
regulator
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Table 1 Continued.
EHD2
ZNF626
PRX
EXOC3L2

1.035
1.039
1.047
1.08

5.00E-05
3.50E-04
5.00E-05
5.00E-05

SERTAD1

1.084

5.00E-05

ZNF134

1.094

5.00E-05

HCN2
BBC3
CNN1
VSIG10L
KCNC3
KLK1
GDF15
KCNN4
RRAS

1.097
1.128
1.192
1.309
1.324
1.357
1.457
1.494
1.534

5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05

ZNF91

1.631

5.00E-05

TNFSF9
ZNF347

1.653
1.674

5.00E-05
5.00E-05

ZNF211

1.711

5.00E-05

SCN1B
KLK13
ZNF551

1.734
1.793
1.835

5.00E-05
5.00E-05
5.00E-05

GP6

1.876

5.00E-05

F2RL3

1.935

5.00E-05

PPP1R13L

1.941

5.00E-05

ZSCAN18
CLEC11A
TNNI3

1.953
2.175
2.553

5.00E-05
5.00E-05
5.00E-05

other
other
other
other
transcription
regulator
transcription
regulator
ion channel
other
other
other
ion channel
peptidase
growth factor
ion channel
enzyme
transcription
regulator
cytokine
other
transcription
regulator
ion channel
peptidase
other
transmembrane
receptor
G-protein coupled
receptor
transcription
regulator
other
growth factor
transporter
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Table 1 Continued.
CYP2S1
SYT3
AXL

2.616
2.652
2.784

5.00E-05
5.00E-05
5.00E-05

ZNF85

2.838

1.00E-04

LRRC4B
ACP5
HKR1

3.301
3.472
3.767

5.00E-05
5.00E-05
5.00E-05

enzyme
transporter
kinase
transcription
regulator
other
phosphatase
Other

The initial analysis of differential expression yielded some interesting results. Many of
the genes displaying a high level of differential expression were transcription factors or
encoded for transmembrane transport proteins, and several canonical signaling
molecules were absent, such as members of the SRC-family kinases or AKT pathway. It is
also noteworthy that many of the genes identified have not been described in cancer
models, which may reflect their status as passenger genes, not directly responsible for
any mechanism of resistance. Further study is warranted to determine what, if any,
influence these genes have in imatinib resistance.

Several genes significantly differentially expressed genes are interesting candidates for
further research. The most downregulated gene was SIGLEC6, a transmembrane
receptor responsible for binding leptin. Two studies have associated increased SIGLEC6
with increased invasiveness, cell proliferation, and inhibition of apoptosis in gestational
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trophoblastic disease and mucosa-associated lymphoid tissue lymphoma[99, 100],
however we report a significant reduction in the transcription of SIGLEC6 in imatinibresistant K562 cells. BRSK1 (-1.151 log2 fold change) a serine/threonine kinase involved
in cell cycle regulation and the DNA damage response that has not been examined in
any human leukemia models. Currently, the only description of BRSK1 expression levels
in human cancer indicates that BRSK1 functions as a tumor suppressor in human breast
cancer, and low levels of BRSK1 correlate with poor prognosis[101].
Aurora C (ARKC) has not been thoroughly investigated in human cancers, despite being a
member of the Aurora Kinase family, of which Aurora A and Aurora B are known to be
involved in oncogenesis. The few studies that have investigated ARKC’s role in cancer
have concluded that increased ARKC activity drives cancer progression[102, 103],
however we observed a downregulation (-1.144 log2 fold change) of ARKC transcription.

The most highly upregulated gene, HKR1 (3.767 log2 fold change), is a Krüppel-type ZNF
gene that has only been investigated in one study, which showed that exposure to
cisplatin induced the transcription of HKR1[104]. Lastly, AXL is a receptor tyrosine kinase
that has been implicated in imatinib resistance. Previous studies have demonstrated
that AXL overexpression is associated with imatinib resistance through a scaffold
function by stabilizing LYN kinase in an active conformation[105, 106], and the findings
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of our RNA-seq experiment demonstrated a 2.784 log2 fold change for AXL transcripts,
which supports previous reports.

2.3.2 Differential Expression Between K562 and K562-NR Cell Lines
Nilotinib is another frontline tyrosine kinase inhibitor commonly prescribed to treat
patients with Ph+ CML. Nilotinib inhibits BCR-ABL 10-30 times more potently than
imatinib does, and also inhibits c-KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB,
MAPK11, and ZAK. Patients who have acquired resistance to imatinib can achieve some
level of response to nilotinib, as a study found that 39% of patients with BP-CML
achieved a hematological response and 27% had a cytogenic response to nilotinib after
failing imatinib treatment[70]. This is possibly due to the fact that nilotinib inhibits all
BCR-ABL kinase domain mutants except T315I, Y253H, E255K/V, and F359C/V[16, 70,
71], however, in a study of imatinib-resistance CML patients 23% of patients treated
with nilotinib developed resistance within two years[14]. Interestingly, patients treated
with nilotinib developed BCR-ABL mutations at a reduced rate compared with patients
treated with imatinib[107], which suggests the possibility that resistance to nilotinib is
dependent upon mechanisms other than target mutation, such as compensatory
signaling pathway activation, BCR-ABL upregulation, a reduction in influx transport
channels, or increase in efflux transport channels. We used RNA-seq to investigate
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differential gene expression between the parental K562 cell line and the K562-NR cell
line, which has evolved resistance to nilotinib. The results are shown in Table 2 below.

Table 2. K562-NR genes found to have significant (p>0.05) differential expression with
respect to parental K562 cells determined by RNA-seq. Differential expression was
analyzed using Cufflinks on the Galaxy platform. Fold change is expressed in terms of
log2.
Gene
BLOC1S3
ZNF257
EID2
ZNF429
TUBB4A
NFIX
ZFP30
FOXA3
HAUS8
ZNF433
C3
GEMIN7
NLRP2
CCDC8
SCAMP4
ASF1B
ZNF607
ARRDC2
ZNF283
PALM3
SIGLEC6
ZSWIM4

Fold Change (log2)
-3.109
-2.888
-2.493
-2.486
-2.422
-2.261
-2.216
-2.12
-2.067
-1.942
-1.876
-1.856
-1.832
-1.753
-1.752
-1.653
-1.65
-1.636
-1.619
-1.619
-1.618
-1.617

p-value
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
1.50E-04
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
3.00E-04
5.00E-05
3.00E-04
5.00E-05

Function
other
other
other
other
other
transcription regulator
other
transcription regulator
other
other
peptidase
other
other
other
other
other
other
other
other
other
other
other
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Table 2 Continued.
RASGRP4
CCDC97
KISS1R
ZNF550
ZNF616
ZNF816
SPHK2
VAV1
ZNF788
ZNF30
ZNF324
EMR2
SIX5
ZNF175
ZNF8
FCGRT
ZNF253
SLC25A41
MIER2
LRG1
ZNF14
ZNF567
MOB3A
EPOR
LRRC8E
ZNF614
PALM
ZNF761
CD3EAP
TBXA2R
PPAN
SCAF1
DPY19L3
ZNF181
SUGP1

-1.608
-1.601
-1.596
-1.595
-1.58
-1.571
-1.495
-1.477
-1.465
-1.46
-1.451
-1.442
-1.442
-1.44
-1.426
-1.406
-1.387
-1.38
-1.361
-1.334
-1.322
-1.316
-1.302
-1.295
-1.288
-1.279
-1.276
-1.26
-1.239
-1.234
-1.211
-1.2
-1.198
-1.188
-1.188

5.00E-05
5.00E-05
1.80E-03
3.90E-03
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
1.50E-04
2.00E-04
2.75E-03
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
4.00E-04
5.00E-05

other
other
G-protein coupled receptor
other
other
other
kinase
transcription regulator
other
other
other
other
transcription regulator
transcription regulator
other
transmembrane receptor
transcription regulator
other
other
other
transcription regulator
other
other
transmembrane receptor
other
other
other
other
other
G-protein coupled receptor
other
other
other
other
other
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Table 2 Continued.
PRR12
ITPKC
NFIX
LDLR
PPP6R1
ZNF320
CD37
ZNF507
NUP62

-1.162
-1.16
-1.152
-1.139
-1.139
-1.123
-1.116
-1.109
-1.094

5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
2.90E-03
5.00E-05
5.00E-05

NR1H2

-1.081

5.00E-05

TICAM1
RASIP1
PIP5K1C
MYADM
KRI1
RDH13
PAK4
PLAUR
ZNF358
UBE2S
CNN1
TEAD2
FLT3LG
ETHE1
KLF16
GLTSCR2
PNPLA6
RPS15
KDELR1
KLK1
HOMER3
HRC
DOCK6
ZNF626

-1.073
-1.069
-1.059
-1.049
-1.023
-1.01
1.01
1.023
1.025
1.026
1.027
1.036
1.044
1.054
1.059
1.061
1.073
1.076
1.081
1.106
1.116
1.127
1.146
1.151

5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
6.00E-04
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
7.00E-04

other
kinase
transcription regulator
transporter
other
other
other
other
transporter
ligand-dependent nuclear
receptor
other
other
kinase
other
other
enzyme
kinase
transmembrane receptor
other
enzyme
other
transcription regulator
other
enzyme
other
other
other
other
transporter
peptidase
other
other
other
other
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Table 2 Continued.
RPL28
SCN1B
RPL13A
AP2S1
JUND
ECH1
DBP
PRX
PEPD
LRRC4B
C19orf79
KCNN4
CERS1
ARHGAP33
PPP1R13L
ZNF296
TNFSF9
A1BG
BBC3
VSIG10L
RRAS
CLEC11A
GDF15
APOC1
APOE
CYP2S1
TNNI3
KLK13
ZNF85
SERTAD1
AXL
PPP1R15A
GADD45B
ACP5
RPL18A

1.159
1.19
1.192
1.21
1.235
1.301
1.338
1.348
1.355
1.385
1.404
1.429
1.43
1.482
1.559
1.588
1.682
1.764
1.781
1.815
2.01
2.08
2.083
2.086
2.208
2.246
2.251
2.437
2.464
2.591
2.679
2.768
3.091
4.7
4.803

5.00E-05
2.20E-03
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
3.00E-03
5.00E-05
5.00E-05
5.00E-05
5.00E-05
3.00E-04
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
3.50E-04
5.00E-05
5.00E-05
5.00E-05
1.10E-03
5.00E-05
5.00E-05

other
ion channel
other
transporter
transcription regulator
enzyme
transcription regulator
other
peptidase
other
other
ion channel
enzyme
transporter
transcription regulator
other
cytokine
other
other
other
enzyme
growth factor
growth factor
transporter
transporter
enzyme
transporter
peptidase
transcription regulator
transcription regulator
kinase
other
other
phosphatase
other
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The RNA-seq results identified 126 genes that were significantly differentially expressed
in the K562-NR cell line as compared to the K562 parental cell line. Interestingly, many
of the genes that are the most significantly differentially expressed have not been
characterized in leukemia, or other human cancers. BLOC1S3 encodes for a protein in
the BLOC1 multi-protein complex, which regulates biogenesis of specific organelles in
the endosomal-lysosomal system. Despite finding that BLOC1S3 has a log2 fold change
of -3.109 in K562-NR cells as compared to K562 cells, no role in any human cancer has
been described as of yet.

One very interesting finding is the downregulation of NFIX, a transcription factor critical
to the regulation of differentiation in the hematopoietic system. The loss of NFIX
perturbed normal gene expression in myeloid and lymphoid cells in-vivo, and NFIX has
been demonstrated to interact with c-JUN in viral disease models[108, 109].
Furthermore, NFIX is a known target of miR-659-3p, a biomarker of improved
progression-free survival in metastatic melanoma[110]. Taken together with our RNAseq results, these studies suggest NFIX is an interesting candidate for further study of its
role in nilotinib-resistant CML.

SERTAD1 is upregulated at a log2 fold change of 2.591 in K562-NR cells compared to
K562 cells. SERTAD1 is a transcription factor interacting with the PHD-bromodomain-1,
and stimulates E2F1/TFDP1 transcriptional activity, rendering the activity of cyclin
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D1/CDK4 resistant to the inhibitory effects of CDKN2A/p16INK4A[111, 112].
Furthermore, SERTAD1 has been shown to inhibit the tumor suppressor protein PTEN in
breast cancer cells, leading to cell survival and increased tumorigenesis by activating the
PI3K/AKT cell proliferation pathway[113]. The significant upregulation in K562-NR cells
and previously established role in tumorigenesis makes SERTAD1 a potential target for
further studies examining the roots of nilotinib resistance in CML.

Another interesting set of genes that are significantly upregulated in K562-NR cells
compared to K562 cells are APOE and APOC1, upregulated at a log2 fold change of 2.208
and 2.086, respectively. Members of the apolipoprotein family, APOE and APOC1 are
primarily involved with binding, internalization, and catabolism of lipoproteins, and
APOC1 has been implicated in the progression of pancreatic cancer[114], while
increased expression of APOE is a biomarker of aggressive acute lymphoblastic leukemia
and has been correlated with short progression-free survival in metastatic colorectal
cancer[115, 116]. APOC1 is also overexpressed in gastric cancer, and treatment with the
histone deacetylase inhibitor vorinostat dramatically reduced the transcription of
APOC1 and induced cell death[117]. Many recent studies have investigated the use of
vorinostat in acute myeloid leukemia, and it may be beneficial to examine its effects in
CML as well.
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Given the large raw data output from RNA-seq experiments, it can be difficult to
determine if perturbation of a particular pathway may underlie resistance to TKI
treatment. We used Ingenuity Pathway Analysis software (Qiagen) to establish
pathways affected by nilotinib resistance, and found that the Eukaryotic Initiation Factor
2 pathway (EIF2) had a significant p-value (p=3.02-3) and a z-score of 2. This indicates
that the differential expression of the genes involved in this pathway predict that the
EIF2 pathway will be activated in K562-NR cells. The genes differentially expressed in
K562-NR cells that predict the activation of the EIF2 pathway are RPL18A, RRAS, RPL28,
PPP1R15A, RPS15, and RPL13A, all of which are upregulated in K562-NR cells compared
to K562 cells. Phosphorylation of EIF2 subunits inhibits protein synthesis and leads to
apoptosis, but interestingly, PPP1R15A binds to PP1 and activates the EIF2 pathway
through dephosphorylation of EIF2-α[117]. Treatment of T-cell Leukemia (T-ALL) with
pegylated-human-arginase I (peg-Arg-I) induced decreased expression of PPP1R15A and
subsequent dephosphorylation of EIF2, resulting in apoptosis in T-ALL bearing
mice[118]. Targeting the EIF2 pathway may be a viable therapeutic option for patients
resistant to nilotinib.

2.2.3 Differential Expression Between K562 and K562-DR Cell Lines
Dasatinib is a second-generation dual BCR-ABL/SRC inhibitor that binds approximately
325 times more tightly to wild type BCR-ABL than imatinib, and can overcome some of
the limitations of imatinib and nilotinib by inhibiting SRC-family kinases whose
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compensatory activation confers TKI-resistance. The results of the DASISION (Dasatinib
versus Imatinib Study in Treatment-Naive CML-CP) clinical trials were recently
published, in which 65% of the dasatinib-treated patients required BCR-ABL mutational
analysis due to treatment issues (no cCCyR within 12 months; no MMR within 12
months; fivefold increase in BCR-ABL1 transcript levels with loss of MMR; loss of CCyR),
and surprisingly, only 9% of dasatinib-treated patients had developed BCR-ABL
mutations[17]. It seems clear that further analysis of BCR-ABL independent dasatinib
resistance is warranted. We developed a dasatinib-resistant K562 cell line (K562-DR) by
culturing K562 cells in escalating concentrations of dasatinib, and performed RNA-seq
on K562-DR cells to compare the transcriptomes of K562-DR cells with the parental K562
cells to identify potential mechanisms of resistance, and identify novel biomarkers of
dasatinib resistance. The significantly differentially expressed genes in K562-DR cells as
compared to K562 cells are shown in Table 3 below.

Table 3. K562-DR genes found to have significant (p>0.05) differential expression with
respect to parental K562 cells determined by RNA-seq. Differential expression was
analyzed using Cufflinks on the Galaxy platform. Fold change is expressed in terms of
log2.
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Gene

Fold Change (log2)

p-value

Function

ZNF433
RASGRP4
ZNF257
ZNF93
CD33
MYO1F
PALM3
ZNF559
B3GNT8
CD320
TSKS
NFIX
CALR
DUS3L
C3
ZNF776

-3.861
-2.08
-1.841
-1.812
-1.725
-1.435
-1.435
-1.297
-1.279
-1.184
-1.165
-1.083
-1.07
-1.068
-1.024
1.011

2.70E-03
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
3.75E-03
5.00E-05
5.00E-04
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05

F2RL3

1.031

5.00E-05

EXOC3L2
LINC00085
SIPA1L3
ZNF91
ZNF600
ZNF432
VSIG10L
CLEC11A
KLF1
ZNF347
ZNF253
ZNF813
ZNF551
ZNF211
KLK1
KCNC3
KLK13

1.036
1.05
1.085
1.088
1.178
1.21
1.248
1.252
1.26
1.261
1.397
1.626
1.772
1.783
1.84
1.861
1.913

5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
2.00E-04
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05

other
other
other
transcription regulator
other
other
other
other
enzyme
other
kinase
transcription regulator
transcription regulator
other
peptidase
other
G-protein coupled
receptor
other
other
other
transcription regulator
other
other
other
growth factor
transcription regulator
other
transcription regulator
other
other
transcription regulator
peptidase
ion channel
peptidase
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Table 3 Continued.
ZNF134
PPAP2C
ZNF671
PPP1R13L
KCNN4
SYT3
ZSCAN18
RPL18A
AURKC
TNNI3
CYP2S1
HKR1
AXL
ACP5
ZNF85
LRRC4B

1.921
2.012
2.101
2.138
2.157
2.181
2.305
2.441
2.45
2.457
2.475
2.584
2.766
2.907
2.973
3.057

5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
1.00E-04
5.00E-05
5.00E-05
5.00E-05
5.00E-05
5.00E-05
7.00E-04
5.00E-05
5.00E-05
2.00E-04
5.00E-05

transcription regulator
phosphatase
other
transcription regulator
ion channel
transporter
other
other
kinase
transporter
enzyme
other
kinase
phosphatase
transcription regulator
other

Dasatinib inhibits SRC-family kinases in addition to BCR-ABL, so one would expect a
different set of genes to be differentially expressed in K562-DR cells as compared to
K562-IR and K562-NR cells. As with the K562-IR and K562-NR cell lines, many members
of the zinc-finger family (ZNF) of transcription factors are differentially expressed,
however the vast majority of ZNF proteins are uncharacterized, and understanding their
function in the context of TKI resistance would be a difficult task.

Ras guanyl nucleotide releasing protein 4 (RASGRP4) is a guanyl nucleotide exchange
factor that activates RAS in mast cells, and is involved with platelet adhesion and cell
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proliferation[119]. Interestingly, RASGRP4 is highly expressed in myeloid cells, and high
expression of RASGRP4 has been observed in acute myeloid leukemia[120, 121].
Interestingly, the results of our RNA-seq experiment show RASGRP4 has a (log2 fold
change of -2.080 in K562-DR cells compared to K562 cells, potentially indicating that the
mechanism of dasatinib resistance is independent of RAS activation. Further
experimentation is needed to confirm our results, but RAS activation likely does not
contribute to dasatinib resistance.

Another interesting finding from our K562-DR RNA-seq experiment is the
downregulation of B3GNT8 (log2 fold change of -1.279) compared to K562 cells. B3GNT8
is an enzyme that regulates the elongation of specific branch structures of
multiantennary N-glycans, and is involved with the biosynthesis of N-glycan precursor
proteins. The results of our RNA-seq experiment demonstrated a significant
downregulation of B3GNT8, but several other studies have demonstrated B3GNT8 plays
a significant role in cancer progression. B3GNT8 silencing reduces cell proliferation,
migration, and metastasis in human glioma cells[122], and human laryngeal carcinoma
cells[123]. Even more interesting is the fact that B3GNT8 was overexpressed in
multidrug-resistant K562 cells, and knockdown of B3GNT8 increased sensitivity to
adriamycin[124]. B3GNT8 has been suggested to increase resistance to chemotherapy
by activating TGF-β signaling, which increases cell proliferation and resistance to
apoptosis[123], however we report no change in TGF-β expression in K562-DR cells as
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compared to K562 cells. This does not exclude the possibility that TGF-β activity is
increased, however it is not possible to draw that conclusion based on transcriptomic
data alone.

Analysis of the RNA-seq data comparing the genes expressed in our K562-DR cell line
and K562 cells shows many of the significantly differentially expressed genes are
upregulated in K562-DR cells despite having been reported to be downregulated in
other cancers, and vice versa. The most differentially expressed gene in our RNA-seq
results is LRRC4B, a protein regulating neurite outgrowth and dendrtitic segmentation in
the developing brain. LRRC4B has been identified as a tumor suppressor in glioma
carcinoma[36, 125], as overexpression of LRRC4 inhibited glioma tumorigenesis and
induced apoptosis. We report an upregulation of LRRC4B (log2 fold change of 3.057),
which conflicts with reports that LRRC4B is a tumor suppressor. LRRC4B may be a
passenger gene, and its upregulation may have no effect on TKI-resistance.

One possible explanation for dasatinib resistance is the upregulation of Aurora Kinase C
(AURKC), which was found to have a log2 fold change of 2.450. AURKC is a
serine/threonine kinase that forms a complex with Aurora B kinase and plays a role in
organizing microtubules in relation to the centrosome during mitosis. Several Aurora A
and Aurora B inhibitors are currently undergoing clinical trials for a variety of human
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leukemias, and treatment of imatinib-resistant CML patients with the Aurora A inhibitor
MLN8237 was shown to significantly increase the efficacy of nilotinib, suggesting Aurora
A activity may contribute to imatinib resistance[126]. AURKC has been noted to be
upregulated in prostate cancer, epithelial cancer, colorectal cancer, and thyroid
cancer[102, 103, 127, 128]. These findings support the hypothesis that AURKC activity
may be involved in dasatinib-resistance in our K562-DR cell line by driving increased cell
proliferation or increasing resistance to apoptosis, and further study is warranted to
investigate AURKC’s involvement in resistance.

RNA-seq comparison of the differentially expressed genes in the K562-DR cell line and
K562 cell line revealed several differentially expressed genes that conflicted with reports
from previous studies. It is important to remember that this study is based on TKIresistant cell lines generated in a cell culture setting, and the resulting findings provide
nothing more than a preliminary direction to explore. Further study of our results with
human patient samples is necessary to validate any novel biomarkers or mechanisms of
resistance.

2.3.4 Common Features of K562-TKIr Cell Lines
Treatment of CML is expensive, and the longer a patient fails to respond to therapy, the
bleaker the prognosis. While it is important to understand the transcriptomic
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differences between imatinib, nilotinib, and dasatinib resistant cell lines, it is equally
important to identify any common themes linking resistance to imatinib, nilotinib, and
dasatinib in order to suggest novel resistance mechanisms or biomarkers shared by
resistant cell lines. We have identified 24 significantly differentially expressed genes that
were identified in K562-IR, K562-NR, and K562-DR cell lines that could serve as potential
biomarkers of TKI-resistance, or contribute to TKI-resistance mechanisms. Table 4 lists
these genes below.

Table 4. K562-TKI-resistant cell line genes found to have significant (p>0.05)
differential expression with respect to parental K562 cells determined by RNA-seq.
Differential expression was analyzed using Cufflinks on the Galaxy platform. Fold change
is expressed in terms of log2.

Gene
ACP5
AURKC
AXL
C3
CD33
CYP2S1
CLEC11A
LRRC4B
KLF1

Fold Change (IR) Fold Change (NR)
3.472
-1.144
2.784
-0.967
-2.589
2.616
2.175
3.301
0.962

4.7
-0.689
2.679
-1.876
-0.711
2.246
2.08
1.385
0.447

Fold Change
(DR)

Function

2.907
2.45
2.766
-1.024
-1.725
2.475
1.252
3.057
1.26

phosphatase
serine/threonine kinase
tyrosine kinase
peptidase
other
enzyme
growth factor
other
transcription factor
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Table 4 Continued.
KLK1
KLK13
KCNN4
JUNB
NFIX
PPP1R13L
RASGRP4
RRAS
TLE2
TNFSF9
TNNI3
TUBB4A
VSIG10L
ZNF85
ZNF433

1.357
1.793
1.494
1
-1.303
1.941
-2.967
1.534
-2.527
1.653
2.553
-1.137
1.309
2.838
-2.288

1.106
2.437
1.429
0.676
-2.261
1.559
-1.608
2.01
-1.451
1.682
2.251
-2.422
1.815
2.464
-1.942

1.84
1.913
2.157
0.731
-1.083
2.138
-2.08
0.937
-1.329
0.87
2.457
-0.915
1.248
2.973
-3.861

peptidase
peptidase
ion channel
transcription factor
transcription factor
transcription factor
other
enzyme
transcription factor
cytokine
transporter
other
other
trancription factor
transcription factor

Based on our RNA-seq results we selected several candidate genes to assess their
significance in TKI-resistance. We chose to ablate AXL as a positive control for our K562IR and K562-NR cell lines, as it had previously been described as a mediator of imatinib
and nilotinib resistance, but had not been previously described in dasatinib
resistance[42, 105]. ACP5 and CYP2S1 were chosen for further investigation, as their
upregulation were novel findings in a CML model.
We first had to confirm whether the increase in transcription correlated with protein
expression. Figure 1 below confirms that protein expression of each gene is increased in
each TKI-resistant cell line.
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K562
K562-IR
K562-NR
K562-DR

+
-

+
-

+
-

+
AXL
ACP5
CYP2S1

GAPDH

Figure 1. Protein expression is increased in TKI-resistant cell lines. Cells were grown to
7.5x105 cells/mL and processed for western blot analysis. AXL, ACP5, and CYP2S1
protein expression was increased in all TKI-resistant cell lines.

AXL is part of the TAM family of receptor tyrosine kinases and is activated upon binding
to the extracellular ligand GAS6. Upon binding, AXL initiates a signaling cascade
influencing cell migration, aggregation, and proliferation[129, 130]. AXL is known to be
integral to the proliferation, metastasis, and contributes to drug resistance in breast,
lung, prostate, ovarian, and many other cancers[131-134]. Because of its high
expression and contribution to drug resistance in so many cancers, AXL is an enticing
drug target for small-molecule inhibitors. However, AXL has been shown to contribute
to imatinib and nilotinib resistance in CML through a LYN-dependent scaffolding
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function[42, 105]. We found AXL transcription to be upregulated in K562-IR (log2 fold
change of 2.784), K562-NR (log2 fold change of 2.679), and K562-DR (log2 fold change of
2.766) cell lines when compared to the parental K562 cell line. Despite having been
implicated in imatinib and nilotinib resistance, AXL has never been implicated in
dasatinib resistance. AXL mediates nilotinib resistance through LYN, and because
dasatinib inhibits the kinase activity of LYN, we sought to determine if knockdown of
AXL using siRNA in K562-DR cells inhibited proliferation relative to the K562 parental cell
line in the same way it does in the K562-IR and K562-NR cells, or if inhibition of AXL
kinase activity could inhibit proliferation in K562-DR cells. The results of the experiment
confirmed previous reports that knockdown of AXL in imatinib and nilotinib resistant
cells resensitized the cells to imatinib and nilotinib in a significant manner. The K562-IR
cells were equally sensitive to imatinib as the parental K562 cells, and the knockdown of
AXL in K562 cells did not have any effect on the proliferation of K562 cells in response to
imatinib (Figure 2A). This indicates that AXL is an important mediator of acquired
imatinib-resistance. Similarly, the knockdown of AXL in K562-NR cells restored sensitivity
to nilotinib in the same manner as seen in the K562-IR cells (Figure 2A & 2B). However,
the resensitization in the K562-DR cell line was modest. The proliferation of K562 cells
and K562-DR cells was largely unaffected by AXL knockdown (Figure 2C), which may be
indicative that the role of AXL in K562-DR cells is not as vital to TKI-resistance as it is in
K562-IR and K562-NR cells, where it acts as a scaffold to stabilize LYN and drive
proliferation[42, 105]. Dasatinib inhibits LYN kinase, so it is unlikely that the
upregulation of AXL mediates resistance through LYN activation. We can conclude that
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AXL does not affect dasatinib resistance, which may proceed through a different set of
compensatory mechanisms than imatinib and nilotinib resistance.

Growth Inhibition
(% Vehicle Control)

A)

Cell Viability
1.5

K562
K562-IR
K562 + AXL siRNA
K562-IR + AXL siRNA
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Figure 2. Knockdown of AXL Preferentially Sensitizes K562-IR Cells to imatinib, and
K562-NR cells to nilotinib, but does not preferentially sensitize K562-DR cells to
dasatinib. Cells were transfected with 100nM AXL siRNA for and seeded in 96-well
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plates for 24 hours before treatment with the indicated inhibitor (n=3). A) Knockdown
of AXL resensitizes K562-IR cells to imatinib. B) Knockdown of AXL resensitizes K562-NR
cells to nilotinib. C) Knockdown of AXL modestly resensitizes K562-DR cells to dasatinib.

A)

K562

K562-IR
Control siRNA
AXL siRNA

+
+
-

+
+

+
+
-

+
+
AXL IB
GAPDH IB

B)

K562

K562-NR
Control siRNA
AXL siRNA

+
+
-

+
+

+
+
-

+
+
AXL IB
GAPDH IB

C)

K562

K562-DR
Control siRNA
AXL siRNA

+
+
-

+
+

+
+
-

+
+
AXL IB
GAPDH IB

Figure 3. Confirmation of AXL Knockdown for XTT Assay. Cells were transfected with
100nM AXL siRNA and dosed with the indicated inhibitors 24 hours later. Seventy-two

52

hours post-transfection 1x106 cells were lysed and subjected to western blot analysis. A)
Knockdown of AXL was successful in K562 and K562-IR cells. B) Knockdown of AXL was
successful in K562 and K562-NR cells. C) Knockdown of AXL was successful in K562 and
K562-DR cells.

Tartrate-resistant acid phosphatase 5 (ACP5) is the only acid phosphatase not inhibited
by L(+)tartrate. Bone resorption and osteoclast differentiation are directed by ACP5
through modulation of focal adhesion kinase (FAK) but ACP5 is also a primary driver of
metastasis and invasiveness in several cancers, and upregulation has been correlated
with poor prognosis. Overexpression of ACP5 drives invasiveness and metastasis in
hepatocellular carcinoma and human melanoma[135, 136], and it is highly upregulated
in gastric cancer, breast cancer, and bone metastases from breast cancer patients[137140]. ACP5 expression has not been studied in any human leukemia, but the significant
upregulation of ACP5 transcription in all three TKI-resistant cell lines compared to the
parental K562 cell line (log2 fold change of 3.472, 4.700, and 2.907 in K562-IR, K562-NR,
and K562-DR cells, respectively) along with the many reports of increased ACP5 levels
coinciding with increased invasiveness and metastasis in other cancers led us to validate
the effect of upregulated ACP5 in TKI-resistance in CML. Interestingly, we observed a
pronounced sensitivity to imatinib and nilotinib (Figure 4A & 4B), but a negligible
resensitization to dasatinib (Figure 4C). The knockdown of ACP5 in K562-DR cells and
K562 cells had almost no effect on the proliferation of either cell line in the presence of
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dasatinib, indicating that ACP5 is not likely a primary driver of dasatinib-resistance
(Figure 4C). In both K562-IR and K562-NR cells, knockdown of ACP5 had a similar effect
as the knockdown of ACP5 in K562 cells, suggesting that the upregulation of ACP5 may
be correlated with acquired resistance to imatinib and nilotinib, respectively (Figure 4A
& 4B). ACP5 is a marker of poor prognosis in other cancers, but the specific mechanism
by which ACP5 mediates oncogenesis is unclear[135, 136, 138, 141]. Future studies may
determine ACP5’s role in cancer pathogenesis and chemoresistance.
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Figure 4. Knockdown of ACP5 Preferentially Sensitizes K562-IR Cells to imatinib, and
K562-NR cells to nilotinib, but does not preferentially sensitize K562-DR cells to
dasatinib. Cells were transfected with 100nM ACP5 siRNA for and seeded in 96-well
plates for 24 hours before treatment with the indicated inhibitor (n=3). A) Knockdown
of ACP5 resensitizes K562-IR cells to imatinib. B) Knockdown of ACP5 resensitizes K562-
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NR cells to nilotinib. C) Knockdown of ACP5 does not resensitize K562-DR cells to
dasatinib.
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Figure 5. Confirmation of ACP5 Knockdown for XTT Assay. Cells were transfected with
100nM ACP5 siRNA and dosed with the indicated inhibitors 24 hours later. Seventy-two
hours post-transfection the cells were lysed and subjected to western blot analysis. A)
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Knockdown of ACP5 was successful in K562 and K562-IR cells. B) Knockdown of ACP5
was successful in K562 and K562-NR cells. C) Knockdown of ACP5 was successful in K562
and K562-DR cells.

Maintaining consistent levels of TKI in the cell is a critical factor affecting the efficacy of
TKI treatment. CYP2S1 is a cytochrome p450 isoform that is upregulated in colorectal
cancer and its high expression is a marker of poor prognosis in colorectal cancer. It has
also been shown to inactivate benzothiazole antitumor compounds in breast and
colorectal cells, and the ablation of CYP2S1 resulted in increased sensitivity to
chemotherapy [142, 143]. In all three of our K562-TKI resistant cell lines we observed a
marked increase in the transcription of CYP2S1 (log2 fold change of 2.616, 2.246, and
2.475 in K562-IR, K562-NR, and K562-DR cells, respectively). We hypothesized that
increased CYP2S1 activity may reduce TKI activity, allowing for drug resistance to evolve,
and siRNA-mediated knockdown of CYP2S1 would restore TKI-sensitivity in the K562-TKI
resistant cells. CYP2S1 knockdown yielded mixed results. In the K562-IR cell line, the
knockdown of CYP2S1 dramatically increased the sensitivity of K562-IR cells to imatinib,
but also increased the resistance of K562 cells to imatinib, suggesting that the increase
in CYP2S1 transcription is not a mechanism by which K562 cells acquire imatinibresistance (Figure 6A). The knockdown of CYP2S1 in K562-NR cells did not have an
appreciable affect on the sensitivity of K562 or K562-NR cells to nilotinib, and we
conclude the CYP2S1 does not confer significant resistance to nilotinib (Figure 6B).
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Knockdown of CYP2S1 did increase the sensitivity of both K562 cells and K562-DR cells
to dasatinib, further illustrating the differences in compensatory mechanisms
contributing to acquired resistance to dasatinib as compared to acquired imatinib and
nilotinib resistance (Figure 6C). Given the kinase inhibition profile of dasatinib, it is not
surprising that the knockdown of a variety of different transcripts would yield results
differing from those of cells treated with imatinib or nilotinib.
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Figure 6. Knockdown of CYP2S1 Preferentially Sensitizes K562-IR Cells to imatinib, and
K562-DR cells to dasatinib, but does not preferentially sensitize K562-NR cells to
nilotinib. Cells were transfected with 100nM CYP2S1 siRNA for and seeded in 96-well
plates for 24 hours before treatment with the indicated inhibitor (n=3). A) Knockdown
of CYP2S1 resensitizes K562-IR cells to imatinib. B) Knockdown of CYP2S1 modestly
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resensitizes K562-NR cells to nilotinib. C) Knockdown of CYP2S1 does not resensitize
K562-DR cells to dasatinib.
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Figure 7. Confirmation of CYP2S1 Knockdown for XTT Assay. Cells were transfected
with 100nM CYP2S1 siRNA and dosed with the indicated inhibitors 24 hours later.
Seventy-two hours post-transfection the cells were lysed and subjected to western blot
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analysis. A) Knockdown of CYP2S1 was successful in K562 and K562-IR cells. B)
Knockdown of CYP2S1 was successful in K562 and K562-NR cells. C) Knockdown of
CYP2S1 was successful in K562 and K562-DR cells.

2.3.5 Emergent Transcripts in the K562-TKI Resistant Cell Lines
The goal of this study is to identify novel biomarkers of imatinib, nilotinib, and dasatinib
resistance, and elucidate potential mechanisms underlying the development of acquired
resistance to TKI therapy. As a patient undergoes treatment with imatinib, nilotinib, or
dasatinib, signaling pathways will be altered in response to the inhibition of the BCR-ABL
signaling pathway, and compensatory pathways may be activated to drive cellular
proliferation, division, or apoptosis. As these signaling pathways are perturbed and
resistance is acquired, the expression of genes will be disrupted to reflect the
restructuring of cellular signaling pathways and other cellular functions to
accommodate sustained proliferation. One potentially useful approach to identifying if a
patient is acquiring resistance to TKI therapy is to monitor the emergence or
disappearance of mRNA transcripts that are associated with TKI resistance. We have
identified six transcripts displaying a fragments per kilobase of transcript per million
mapped reads (FPKM, which is an expression of the raw number of transcripts read in a
given sample) of greater than ± 10 in the K562-TKI resistant cell lines in relation to the
parental K562 cell line, reflected in Table 5 below.
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Table 5. Emergence or Disappearance of mRNA Transcripts as Tyrosine Kinase
Inhibitor Resistance is Acquired. Raw transcript measurements from RNA-seq analysis
are shown in FPKM. The denoted change for K562-IR, K562-NR, and K562-DR cell lines is
relative to the parental K562 cell line.
Cell Line
K562-IR

K562-NR

K562-DR

Gene
CLC
GNG8
MIR3940
MIR637
RLN3
SGK110
SNORD88A
SNORD88B
SNORD88C
ZNF350
GNG8
IGFL2
RLN3
SNORD33
SNORD35A
SNORD88C
CREB3L3
GNG8
SGK110

FPKM Change Relative to K562
-19.404
79.085
8.49E+03
1.15E+04
12.707
13.447
1.07E+04
1.08E+04
-1.09E+04
-17.451
45.339
10.626
43.822
2.78E+04
7.22E+04
-1.31E+04
15.809
40.468
17.982

The loss of CLC in K562-IR cells is somewhat intriguing, as it is a lysophospholipase
associated with inflammation and has been implicated in myeloid differentiation[144],
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but very little is known about its potential role in leukemia. RLN3 (expressed in K562-IR
and K562-NR cells) and SGK110 (expressed in K562-IR and K562-DR cells) have never
been described in any cancer studies, and SGK110, an SH3-domain binding
serine/threonine kinase, has never been characterized in any capacity. Further study
into the functions of these genes in TKI-resistance may yield promising results. The loss
of ZNF350 expression in K562-NR cells is noteworthy, as methylation of the promoter
region and subsequent loss of ZNF350 expression has been reported in tamoxifenresistant breast cancer cells. Treatment with 5-aza-2ꞌdeoxycitidine significantly reduced
promoter methylation, and the resulting increase in ZNF350 expression corresponded
with tamoxifen re-sensitization in MCF-7 breast cancer cells[145]. Perhaps a similar
event is the reason for ZNF350 transcriptional downregulation. The other novel
transcript found in K562-NR cells, IGFL2, has been shown to be upregulated in Sezary
syndrome, a rare form of CD4+ cutaneous T-cell lymphoma, although no causative
explanation was reported[146]. CREB3L3 is a protein belonging to the cAMP-dependent
family of transcription factors, which is activated by ER-stress in hepatocellular
carcinoma. Activated CREB3L3 then promotes cell proliferation via c-JUN mediated
activation of AP-1 target genes[147]. CREB3L3 is also upregulated in response to
treatment with the putative antimetastatic agent silibinin, suggesting a possible role in
drug-resistance in hepatocellular carcinoma[148].
The modest increase in transcript levels of GNG8 in K562-IR, K562-NR, and K562-DR cell
lines is noteworthy because it is a known cofactor in the WNT/β-catenin signaling
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pathways, and has also been implicated in chronic lymphocytic leukemia
pathogenesis[149]. The WNT/β-catenin pathway is activated by BCR-ABL in CML
pathogenesis, but TKI-mediated inhibition of BCR-ABL signaling abrogates WNT/βcatenin activity in imatinib-sensitive cells, and pharmacological inhibition of the WNT/βcatenin pathway in combination with imatinib treatment dramatically reduced the
amount of leukemia stem cells in a mouse model of CML[150]. Recently, sustained WNT
signaling was demonstrated in TKI-resistant CML stem cells via expression of the tumor
necrosis factor ligands CD70 and CD27[151]. Activation of the WNT/β-catenin signaling
pathway in imatinib-resistant CML has been reported in many studies, but has not been
reported in nilotinib or dasatinib resistant CML patients. It is tempting to speculate that
emergence of the GNG8 transcript may underlie activation of the WNT/β-catenin
signaling pathway, conferring resistance to imatinib, nilotinib, and dasatinib, but further
study is necessary to tease apart any potential involvement of GNG8 in WNT/β-cateninmediated TKI-resistance.

The differential expression of miR3940, miR637, snORD33, snORD35A, snORD88A,
snORD8B, and snord88C transcript levels are tremendous in comparison to the other
emergent transcripts. miR3940 has been shown to be downregulated in non-small cell
lung carcinoma[152], but those data were based on a correlation between decreased
miR3940 expression and the increasing severity of tumor growth and no oncogenic role
was established. However, miR637 has been demonstrated to have a significant role in
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the inhibition of hepatocellular carcinoma progression through the disruption of STAT3
signaling, which rescues cells from apoptosis and promotes cell proliferation[153]. It is
surprising that both miRNAs were found to be significantly overexpressed in the K562-IR
cell line, when they were found to be significantly downregulated in lung and liver
cancer tissue in the studies previously described. snORD88A, snORD88B, and snORD88C
are small non-coding RNA’s that function to modify the biogenesis of other small
nuclear RNA’s. Very little is currently known about the function of snORD88A,
snORD88B, and snORD88C, but it is predicted that they can suppress gene expression in
a miRNA-like manner[154]. Interestingly, transcription of snORD88C is lost in K562-NR
and K562-DR cells, while it is significantly upregulated in K562-IR cells. Regardless, a
complete understanding of the function of these transcripts is not always necessary to
use as a benchmark for therapeutic performance, and miR3940, miR637, snORD88A and
snORD88B could have potential as biomarkers of imatinib resistance.

2.3.6 Novel Fusion Transcripts in the TKI-Resistant Cell Lines
In addition to differential expression testing and the emergence or disappearance of
transcripts in the K562-TKI resistant cell lines relative to the parental K562 cell line, the
detection of novel fusion genes represents a novel biomarker avenue to detect
emerging TKI-resistance. Fusion genes are known drivers of oncogenesis, and the
detection of fusion transcripts has long been an indicator of prognosis in various

65

cancers. Chronic myelogenous leukemia is induced by the development of the BCR-ABL
fusion gene, and oncogenesis can be spurred by the fusion of a gene to a strong
promoter region, allowing for increased transcription of an oncogene, or elimination of
an inhibitory residue, which induces a constitutively active oncogene. In every replicate
from each of our conditions we identified transcription of the BCR-ABL fusion gene,
which served as an internal positive control for gene fusion detection. Additionally, we
identified several novel fusion genes in our TKI-resistant cells that have not been
previously reported.

We used the DeFuse software to identify fusion genes present in our TKI-resistant cell
lines in an effort to identify potential drivers of resistance or biomarkers that could be
potentially used to detect impending TKI resistance at an early stage. Novel fusion genes
detected in our RNA-seq results are listed in Table 6 below.

Table 6. Novel Fusion Genes Present in K562-TKI Resistant Cell Lines. Novel fusion
genes identified from RNA-seq analysis in K562-IR, K562-NR, and K562-DR cells are
shown. Fusion genes were identified using DeFuse software on the Galaxy platform
through the Minnesota Supercomputing Institute.
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Cell Line

Gene 1

Gene 2

Gene 1
Chromosome

Gene 2
Chromosome

K562-IR

ANAPC1

RMND5A

11

8

RPL11

TCEB3

23

23

CTSC

RAB38

8

8

K562-NR

RPL11

TCEB3

23

23

K562-DR

CTSC

RAB38

8

8

RPL11

TCEB3

23

23

We were able to identify three fusion genes not previously described in a CML model,
which were not present in the parental K562 cell line. ANAPC1-RMND5A had previously
been reported in BT474 and SKBR3 breast cancer cells, and had been identified as a
mutation driving oncogenesis[155], and could potentially play a role in imatinib
resistance in our K562-IR model. The RPL11-TCEB3 fusion had not yet been described in
CML cells, but its identification was not surprising, as they are found on the same locus.
The detection of the RPL11-TCEB3 fusion transcript was not a read-through error,
despite their proximity on the same locus. Interestingly, both RPL11 and TCEB3 have
been described as tumor-suppressors in other cancers[156, 157]. Although it is outside
our current scope, it would be interesting to determine whether the fusion of these
genes results in a functionally inactive protein that undermines their ability to suppress
tumorigenesis. The last fusion gene detected was CTSC-RAB38, which is found in
approximately 20% of renal cell carcinoma patients[158].
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Functional studies are required to determine any contribution these novel fusion
transcripts may have to TKI-resistance in CML, but their identification may allow them to
be implemented as biomarkers of treatment failure. It may be possible to identify
emergence of these novel fusion proteins using transcriptomics or mass spectrometry to
monitor a patient’s response to treatment, or predict if a patient will elicit a favorable
response to a particular TKI prior to treatment.

2.3

Conclusions

We report a transcriptomics-based characterization of a cell-culture model of acquired
resistance to imatinib, nilotinib, and dasatinib, respectively, in chronic myelogenous
leukemia. Although there are differences in transcription profiles between the TKIresistant cells, we report twenty-four genes all three cell lines significantly differentially
expressed with respect to the parental K562 cell line. Additionally, we report the
emergence and disappearance of transcripts in our TKI-resistant cell lines with respect
to the parental cell line, with GNG8 a common emergent transcript. Finally, we report
novel fusion transcripts unique to each imatinib, nilotinib, and dasatinib. This
bioinformatics approach must be followed up with data from patient samples, but the
results of our cell-culture model may serve as a guide to direct further research into the
acquisition of resistance to imatinib, nilotinib, and dasatinib, and lead to the
development of alternative or novel combinational chronic myelogenous leukemia
therapies.
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CHAPTER 3.

IDENTIFICATION OF PROTEOMIC DIFFERENCES BETWEEN WILD-TYPE CML

CELLS AND CML CELLS RESISTANT TO TYROSINE KINASE INHIBITORS

3.1

Introduction

Proteomics is the study of the proteins present in a particular sample, which extends the
understanding of the physiological functions of the genes that transcribe them. Proteins
are modified through posttranslational modifications that alter the structure and
activity of the proteins and can affect the rates of degradation of proteins in a complex
spatiotemporal manner. The constant changes in rates of degradation and synthesis of
proteins makes proteomics a dynamic field much more complex than genomics or
transcriptomics. Tyrosine kinase inhibitors enact cellular change by acting at the
proteinlevel; therefore it is prudent to study the changes occurring at the cellular level
at which most signaling occurs, the protein level. In this chapter I examine the
proteomic differences between the parental K562 cell line and the K562-IR, K562-NR,
and K562-DR cell lines, respectively, using Sequential Window Acquisition of all
Theorectical Spectra mass spectrometry (SWATH-MS).
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3.2

Materials and Methods

Generation of TKI-resistant Cell Lines. Described in Chapter 2.

Sample Preparation for Proteomic Analysis. K562, K562-IR, K562-NR, and K562-DR cell
lines were thawed and grown in IMDM supplemented with 10% FBS and 0.1%
penicillin/streptomycin. The cells were grown to a density of ~7.5x105 cells/mL, and
1x107 cells of each cell line were centrifuged and washed three times with ice-cold PBS.
The cells were then resuspended in lysis buffer (50mM ammonium bicarbonate pH 7.0,
4mM EDTA, phosphatase inhibitors (Roche)) and immediately incubated at 95°C for five
minutes. The cells were then sonicated for 30 minutes in a water-bath and the insoluble
fraction was separated from the cell lysate by centrifugation at 1.5x10 3 RPM for 20
minutes at 4°C. Each sample was reduced (20mM DTT for 1 hour at 60° C), and alkylated
(40mM IAA for 30 minutes at room temperature, protected from light). Reactions were
quenched by adding DTT to a final concentration of 10mM. The samples were then
trypsin digested overnight at 37° C at a ratio of 1:50 (w/w). Samples were then cleaned
up using MCX stage-tips[143, 159] and resuspended in Triple TOF sample buffer (90%
water/ 10% acetonitrile/ 0.1% formic acid) to a final concentration of 0.15 mg/mL and
transferred to mass spectrometry sample vials (Eksigent).
SWATH-MS analysis. Eight hundred nanograms of each sample were loaded onto a 3
µm x 10 cm ChromXP™ C-18 chip column (particle diameter 3 µm, pore size 120Å) in
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serial mode with a Eksigent 400 cHIPLC system. The run gradient was over 90 min with a
gradient from 5% to 35% buffer B (buffer A: LC-grade water + 0.1% formic acid; buffer B:
LC-grade acetonitrile + 0.1% formic acid) at a flowrate of 300 nl/min. The Eksigent 400
cHIPLC system was coupled to a TripleTOF 5600 (SCIEX) mass spectrometer. The
acquisition parameters were as follows: one 50 msec MS scan (at >30K resolution),
followed by 34 SWATH windows of 25 da each at 50 msec accumulation time for m/z
400-1250. The total cycle time was ~1.8 sec and each analysis was performed in
duplicate.

Analysis of SWATH-MS Data Using DIA-Umpire. DIA files were first converted to
centroided mzXMLs with the Sciex MS Data Converter. DIA Umpire signal extraction
module was used to detect peptide fragment features based on m/z and retention time
information and construct 'pseudospectra' for potential peptides[160]. The Q1 and Q3
level pseudospectrum MGF file outputs from DIA Umpire SE were converted to indexed
mzXML and searched against a human swissprot reference database using the Comet
and xtandem! native and xtandem! kscore algorithms via the trans proteomic pipeline
(v4.8.0). Search outputs were converted to pep.xml files and peptide probability
modeling was performed using the xinteract peptide prophet algorithm (using high mass
accuracy binning, retention time information, and non-parametric decoy modeling).
Search results corresponding to one raw file generated by the three separate algorithms
were combined using the interprophetparser. The final, combined search result was
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loaded into Skyline software to construct an peptide transition assay library of all
peptide spectral matches with probability scores > 0.95. The five peptide fragments with
highest intensities (excluding fragments within 3 residues of either the C- or N-terminus)
were used to represent each peptide. The assay list was filtered to include only
proteotypic (e.g., unique to a single protein sequence, non-degenerate) peptide
sequences and decoys with shuffled sequence were appended to the list. This final
transition assay list was extracted against each of the individual DIA files for targeted reanalysis and peptide quantification in Skyline. False discovery rates were estimated with
the mprophet algorithm feature, and peptides with FDR < 0.01 were exported for
statistical processing in MSSTATS (v3.2.2). Data were normalized to median signal
intensities and protein inference was estimated using the Tukey's Median Polish based
protein abundance modeling algorithm. Pairwise comparisons were calculated between
experimental groups of interest, and Bonferonni adjusted p-values were used to control
for multiple testing effects.

3.3

Proteomics as a Cancer Biomarkers

One of the primary limitations of transcriptomics-based biomarker identification is that
the output does not reveal any information about the activity of the resulting protein, or
even if the protein is ultimately translated. miRNA and other non-coding RNA play a
substantial role in mRNA translation and protein synthesis[161-163], and dynamic
changes in protein degradation rates further complicate predicting protein levels based
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on transcriptomic data. There is a need to identify protein activity levels in disease
pathology, as mRNA levels do not strongly correlate with protein levels, and it is
impossible to determine the activity of a protein from its mRNA[164]. Recent advances
in mass spectrometry-based proteomics have dramatically improved the ability to
detect proteins and their post-translational modifications in complex protein mixtures,
such as cell lysate. Mass-spectrometry based proteomics has traditionally been
dominated by two complimentary modes of detection. Bottom-up discovery
proteomics, or “shotgun proteomics”, utilizes high-performance liquid chromatography
in combination with a tandem mass-spectrometer to identify peptides from complex
mixtures based on the spectral profile of the MS2 fragmentation pattern. Shotgun
proteomics is useful for determining the proteins in a given sample, but is limited by the
large m/z range over which the instrument is required to detect fragment ions. The
resulting data is heavily biased toward the most abundant MS1 precursor peptides, and
excludes low-abundance proteins from being identified. Targeted proteomics, or
selected-reaction monitoring (SRM), is the monitoring of the products of a precursor ion
at a specific m/z range in an effort to quantify a specific protein in a sample. Targeted
proteomics requires the researcher to know the identity of their protein of interest in
order to monitor its detection, whereas shotgun proteomics is useful for discovering
proteins present in a sample. A recent advance in mass-spectrometry has effectively
combined the advantages of SRM and shotgun proteomics into one method, allowing
for unbiased global proteomic profiling.
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3.3.1 Use of SWATH-Mass Spectrometry in Biomarker Research
Sequential Window Acquisition of All Theoretical Spectra (SWATH-MS) is a dataindependent acquisition (DIA) mass-spectrometry method capable of detecting all MS2
fragment ions generated from all MS1 precursor ions eluting from an HPLC column in a
given sample, thus generating a permanent digital library of all detectable fragment ion
spectra within the instrument’s dynamic range. In SWATH-MS experiments, the mass
spectrometer steps through 2-4 second cycles in which all precursor ions eluting from
the HPLC column at a given time are fragmented, and the mass spectrometer rapidly
detects the resulting fragment ions. Unlike in Data Dependent Acquisition (DDA)
methods, where only a set of the most abundant MS1 precursor ions are fragmented for
MS2 analysis, DIA offers an opportunity to both identify and quantify an enormous
number of proteins in a complex protein mixture, such as cell lysate, combining the level
of peptide coverage afforded by shotgun proteomics with the sensitivity and
quantification of SRM. SWATH-MS is a very versatile tool for cell biology research,
having been used to identify 14-3-3 protein-binding partners, biomarkers of prostate
cancer aggressiveness, and even cannabinoid metabolites found in urine[165-167].
Transcription of a gene does not significantly correlate with its translation or protein
activity upon translation[164, 168, 169], and the bias of shotgun proteomics toward
high abundance proteins makes the use of SWATH-MS an ideal solution to identify novel
protein biomarkers of TKI-resistance in chronic myelogenous leukemia that may be
present at lower abundances and undetectable using a conventional DDA approach. We
used SWATH-MS to probe the proteome of K562, K562-IR, K562-NR, and K562-DR cell
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lines for potential biomarkers of TKI resistance, and compare the protein composition of
each cell line with their transcriptome.

3.4 Proteomic Changes in K562 Cells as Compared to K562-TKI Resistant Cells
We sought to compare the transcriptomic changes in K562 cells with evolved resistance
to imatinib, nilotinib, and dasatinib with the proteomic changes in the same cell line to
determine if the transcription levels correspond with the observed protein levels. The
complex relationship between transcription and translation has been well documented,
as miRNA and other factors effect the translation of mRNA into proteins and dynamic
changes in the rates of protein degradation affecting protein levels after translation.
SWATH-MS was used to quantify the proteins present in K562 cells and K562-TKIR cells.
DIA-Umpire was then used to extract pseudo-MS spectra. DIA-Umpire is an open-source
software program that allows for untargeted peptide identification from DIA mass
spectrometry data without the use of a spectral library created from DDA data. DIAUmpire works by incorporating several computer algorithms to detect all possible
precursor fragment ions signals in MS1 and MS2, including unfragmented ions in MS2
data. The algorithm then computes the Pearson correlation coefficient of the retention
time and peak apex of eluting fragment ions to determine the likelihood that a
particular fragment ion corresponds to a precursor ion. The precursor-fragment groups
are then grouped together as pseudo-MS/MS spectra that are searchable in
conventional protein databases[160]. The Q1 and Q3 level pseudo-spectrum MGF file
outputs from DIA Umpire SE were converted to indexed mzXML and searched against a
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human swissprot reference database using the Comet and X!Tandem native and
X!Tandem kscore algorithms via the trans proteomic pipeline (v4.8.0)[170]. Search
outputs were converted to pep.xml files and peptide probability modeling was
performed using the xinteract peptide prophet algorithm (using high mass accuracy
binning, retention time information, and non-parametric decoy modeling). Search
results corresponding to one raw file generated by the three separate algorithms were
combined using the interprophetparser. The final, combined search result was loaded
into Skyline software to construct a peptide transition assay library of all peptide
spectral matches with probability scores > 0.95. The five peptide fragments with highest
intensities (excluding fragments within 3 residues of either the C- or N-terminus) were
used to represent each peptide. The assay list was filtered to include only proteotypic
(e.g., unique to a single protein sequence, non-degenerate) peptide sequences and
decoys with shuffled sequence were appended to the list. This final transition assay list
was extracted against each of the individual DIA files for targeted re-analysis and
peptide quantification in Skyline[171, 172]. False discovery rates were estimated with
the mprophet algorithm feature, and peptides with FDR < 0.01 were exported for
statistical processing in MSSTATS (v3.2.2)[171, 172]. Data were normalized to median
signal intensities and protein inference was estimated using the Tukey's Median Polish
based protein abundance modeling algorithm. Pairwise comparisons were calculated
between experimental groups of interest, and Bonferonni adjusted p-values were used
to control for multiple testing effects. The construction of the spectral library using DIAUmpire and analysis of SWATH-MS data using Skyline was performed by Dr. Sarah
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Parker. Across all of the TKI-resistant samples, we found 69 proteins that were
significantly downregulated compared to the parental K562 cells (p<0.05), and 32
proteins that were significantly upregulated compared to the parental K562 cells
(p<0.05). We chose to include proteins with a log2 fold change of ±2 in our report, and
significantly differentially expressed proteins in K562-IR cells as compared to K562 cells
are listed in Table 7 below.

Table 7. K562-IR proteins found to have significant (p<0.05) differential expression
with respect to parental K562 cells determined by SWATH-MS. Differential expression
was analyzed using Skyline, and statistics were compiled using MSStats.

Protein

log2 Fold Change

p-value

PHB2
PURA
CAST
AHNAK2
KRT6B
NUCKS1
CA1
KRT10
DSC1
KRT1
KRT14
KRT9
CALML5
DSG1
KRT2

2.463
2.378
-2.441
-2.524
-2.716
-2.787
-3.017
-3.229
-3.422
-3.515
-3.734
-3.976
-4.691
-5.044
-5.047

4.76E-02
4.34E-05
3.66E-02
3.39E-03
3.32E-04
2.15E-03
1.14E-04
2.71E-05
1.74E-02
7.16E-07
5.10E-03
7.52E-05
1.25E-03
5.64E-03
1.47E-03
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Table 7 Continued.
KRT5
DSP
KRT16
JUP

-5.167
-6.283
-6.917
-7.68

5.70E-03
2.35E-03
2.48E-02
3.16E-02

One striking feature of the K562-IR cell line is the increased protein levels of only two
proteins, and seventeen downregulated proteins. There are also six proteins that have a
log2 fold change of -5.0 or more, which is more differentially expressed than any gene
found in our RNA-seq experiments. Of note are the most positively and negatively
differentially expressed proteins. PHB2 is a mediator of transcriptional regulation, and
mutational studies have demonstrated its roles in driving ERK1/2 signaling, inhibition of
apoptosis, release from the G1/S checkpoint in mitosis, and protein stabilization[173175].

On the other hand, the significant loss of JUP, DSG1, and DSP, along with eight proteins
members of the keratin-family is interesting; all eleven proteins have been shown to
mediate cell to cell adhesion by forming desmosomes[176-178], the loss of which is a
common feature of cancer[179]. Part of the desmosome complex is the metastasissuppressing protein VE-cadherin, which forms a complex with JUP and several keratins
to mediate cell-cell adhesion and prevent cell motility, however, loss of VE-cadherin has
long been known to be a biomarker of CML development[180]. This is the first reported
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loss of the remaining components of the desmosome complex, which may be indicative
of their role in acquired imatinib resistance. A hallmark of the metastatic process in
recurrent cancer is the epithelial-to-mesenchymal transition (EMT), which is
characterized by a loss of E-cadherin, and upregulation of N-cadherin (EN-switch)[181].
N-cadherin forms a cytoplasmic complex with β-catenin, increasing Wnt-mediated βcatenin nuclear translocation and transcriptional activity, and plays a role in TKI
resistance in leukemia stem cells (LSC) in CML cells co-cultured with bone marrow
stromal cells[182]. The loss of the desmosome complex could potentially be a byproduct of the K562-IR cell line acquiring a phenotype similar to LSCs in the context of
the bone marrow microenvironment, which helps to confer imatinib resistance.

The overexpression of AXL could potentially mediate the loss of the desmosome
complex in K562-IR cells. EMT is the process by which cells metastasize, and the loss of
the desmosome is necessary for EMT to occur. AXL has been shown to be integral to
EMT progression and the disruption of cell-cell adhesion[183]. The overexpression of
AXL is also highly correlated with increased Wnt and TGFβR signaling, which are also
upregulated during EMT, and associated with the loss of the desmosome complex and
the EN-switch[184]. The association between AXL upregulation and the loss of the
desmosome complex would mark a yet-uncharacterized link between the receptor
tyrosine kinase and the desmosome complex. Leukemia stem cells are intrinsically
resistant to imatinib, and the upregulation of AXL could potentially be an important step
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in the disruption of the cell-cell adhesion anchoring LSCs in the bone marrow, allowing
TKI-resistant CML cells to enter the bloodstream. Future studies should profile the
expression of EMT-related genes such as vimentin and snail in response to AXL
upregulation to determine in AXL upregulation corresponds with the induction of EMTrelated gene expression. Additionally, it would be interesting to determine the
molecular time-line of AXL upregulation and the loss of the desmosome complex, which
could be easily determined using standard western blotting. The association of AXL
upregulation and the induction of Wnt/TGFβ signaling has not been described in CML
models, and it would be very interesting to explore the possibility that AXL upregulation
serves as a conduit to drive cell proliferation by activating the Wnt/TGFβ pathway, and
the loss of the desmosome is a consequence. Leukemia stem cells are intrinsically
resistant to imatinib, so it raises the possibility that resistance to imatinib in vivo
progresses through upregulation of AXL and the corresponding loss of the desmosome
complex and the release of differentiated TKI-resistant CML cells from the bone marrow.
AXL activates the MAPK pathway, which enhances WNT signaling[185]. It would be
interesting to dissect the interaction between AXL and WNT, and if it proceeds through
MAPK signaling, resulting in the loss of the desmosome and acquisition of an EMT-like
phenotype.

AXL

MAPK

WNT/T
GFβR

Des.
Complex
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Figure 8. Proposed Model of K562-IR Resistance. AXL activates the MAP Kinase
pathway, activating WNT/TGFβR, which leads to the downregulation of the proteins
composing the desmosome complex, allowing for cell motility to increase.
Table 8. K562-NR proteins found to have significant (p<0.05) differential expression
with respect to parental K562 cells determined by SWATH-MS. Differential expression
was analyzed using Skyline, and statistics were compiled using MSStats.

Protein
SLC25A3
KRT14
RPN1
PHB2
TUBA4A
LRRC59
VDAC2
COMT
VDAC1
RHOA
HBE1
VAPA
RAB33B
RAB35
PHGDH
PEX19
PTMS
PAGE5
UQCRH
MFAP1

log2 Fold
Change
4.308
3.798
3.603
3.546
3.478
3.146
3.084
2.938
2.647
2.549
2.218
2.202
2.062
2.053
2.006
-2.041
-2.045
-2.089
-2.125
-2.138

p-value
1.93E-04
4.80E-03
3.40E-02
1.53E-02
1.31E-03
1.37E-04
1.93E-03
2.55E-02
3.27E-05
4.35E-03
1.66E-06
1.08E-04
3.09E-04
4.83E-05
5.59E-04
1.50E-03
2.06E-05
2.04E-05
2.77E-05
8.63E-03
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Table 8 Continued.
BTF3
NOLC1
TMSB10
NACA2
RPS21
DNAAF2
AHNAK2
POLR2I
SH3BGRL3
TIMM8A
ATOX1
ZC3H18
GRN
TPM4
ZPR1
C14orf142
SH3BGRL
AHNAK
MYL6
COX6B1
CCDC86
TRIP6
KIAA0101
RBM3
ZNF428
NUCKS1
CAST
BTF3L4

-2.148
-2.149
-2.159
-2.237
-2.238
-2.251
-2.284
-2.322
-2.338
-2.34
-2.42
-2.483
-2.502
-2.533
-2.576
-2.591
-2.645
-2.747
-2.833
-2.875
-2.876
-3.16
-3.368
-3.475
-3.563
-3.704
-3.727
-4.169

5.86E-05
5.43E-04
2.36E-04
1.70E-06
1.13E-03
1.00E-01
4.13E-03
5.79E-02
1.05E-02
5.16E-03
4.63E-04
2.36E-02
5.39E-03
1.51E-04
4.28E-02
3.82E-05
4.31E-05
3.25E-01
3.17E-04
4.47E-04
5.17E-02
1.80E-01
2.63E-04
2.80E-02
1.09E-03
7.28E-04
9.19E-03
1.78E-04

The K562-NR cells followed suit with the results from our RNA-seq analysis and showed
the most differential expression of proteins of the three conditions as compared to the
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parental K562 cell line. However, the results also demonstrated a majority of proteins
downregulated, as 33 of 48 significantly differentially expressed proteins bearing a log2
fold change of ± 2 were downregulated. One of the most significantly upregulated genes
was PHB2, a trait shared with the K562-IR cells. However, in the K562-NR cell line there
was not a common trend of desmosome-related proteins in the downregulated group,
with the only member of that group being KRT14, which was highly upregulated. A
common feature of several upregulated proteins is their involvement in mitochondrial
membrane transport, as VDAC1 and VDAC2 are upregulated in many cancers and their
inhibition promotes apoptosis[186], and SLC25A3, a protein integral to phosphate
transport from the cytosol to the mitochondrial matrix, has been reported to be
significantly overexpressed in blast phase CML as compared to chronic phase CML[187].
Similarly, NUCKS1 upregulation is a biomarker of recurrence-free survival in cervical
squamous carcinoma, and its downregulation is a predictor of vincristine-resistance in
childhood acute lymphoblastic leukemia[188, 189].

CAST, also known as calpain-10, is significantly downregulated in K562-NR cells as
compared to K562 cells. CAST has been shown to be a negative regulator of apoptosis in
pancreatic cells, and may serve a similar purpose in K562-NR cells[190]. Although there
has been no established role of these proteins in CML, it is worth noting there has been
some role established on other cancer models that may translate to nilotinib resistance
in K562 cells.
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Table 9. K562-DR proteins found to have significant (p<0.05) differential expression
with respect to parental K562 cells determined by SWATH-MS. Differential expression
was analyzed using Skyline, and statistics were compiled using MSStats.

Protein
SLC25A3
COMT
ASNS
RPN1
PHB2
RAB10
SLC25A5
LRRC59
NOP16
VDAC1
TK1
CBS
VDAC2
VAPA
GCN1L1
KRT2
C14orf142
SH3BGRL3
CCDC86
PAGE5
ZC3H18
SH3BGRL
PTMS
TIMM8A
TRIP6
MYL6
PNISR

log2 Fold Change
3.26
3.242
3.184
2.887
2.846
2.727
2.721
2.486
2.287
2.222
2.169
2.155
2.154
2.093
2.06
-2.018
-2.147
-2.209
-2.22
-2.242
-2.243
-2.254
-2.27
-2.385
-2.391
-2.417
-2.461

p-value
2.43E-04
3.35E-02
3.27E-03
6.42E-02
3.10E-02
9.17E-05
1.13E-03
3.45E-04
5.08E-02
6.55E-05
1.08E-02
3.82E-02
7.19E-03
1.32E-04
3.03E-01
3.58E-02
8.04E-05
1.27E-02
1.02E-01
1.54E-05
3.25E-02
8.12E-05
1.36E-05
4.82E-03
2.04E-01
5.88E-04
1.03E-01
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Table 9 Continued.
ZPR1
AHNAK
CALML5
DSG1
NUCKS1
CAST
BTF3L4

-2.639
-2.772
-2.899
-3.295
-3.384
-3.46
-3.932

3.99E-02
3.22E-01
3.27E-03
1.86E-02
1.03E-03
1.19E-02
2.24E-04

The K562-DR cells profile of significantly differentially expressed proteins shared many
common features with the K562-NR cells, namely, the significant downregulation of
BTF3L4, CAST, NUCKS1, AHNAK, ZPR1, TIMM8A, SH3BGRL, ZC3H18 and MYL6, along with
the upregulation of SLC25A3, VDAC1 and VDAC2, LRRC59, and VAPA. The upregulated
proteins in both conditions are involved in metabolic reprogramming, and might be
indicative of the evolution of a more general cancer-survival reprogramming. Of note is
the high level of TK1 in K562-DR cells, a thymidine kinase, and biomarker of poor
prognosis in chronic lymphocytic leukemia, breast, gastric, rectal, colorectal, lung, brain
cancer, and hepatoma[191, 192].

K562-DR cells also shared common downregulated proteins with K562-IR cells, such as
DSG1, and CALML5, the ubiquitination of which has been linked to breast cancer
carcinogenesis in premenopausal women[193]. Compared to the transcriptomic data,
which contained twenty-four commonly differentially expressed genes, the proteomic
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analysis of TKI-resistant K562 cells yielded only eighteen commonly significantly
differentially expressed proteins across all three conditions.

Table 10. Common proteins in TKI-resistant K562 cells found to have significant
(p<0.05) differential expression with respect to parental K562 cells determined by
SWATH-MS. Differential expression was analyzed using Skyline, and statistics were
compiled using MSStats.

Protein

IR log2 Fold Change

NR log2 Fold Change

DR log2 Fold Change

ABCE1
ASNS
CA1
CAST
DDX6
DDX21
EIF4B
FKBP3
FRA10AC1
IGF2BP1
MYL6
NFYA
NUCKS1
PHB2
SLC25A3
SLC3A2
TPM4
VTN

1.062
1.954
-3.017
-2.441
1.149
1.19
1.116
-1.322
-1.439
1.097
-1.084
-1.222
-2.787
2.463
1.526
1.229
-1.231
-1.792

1.649
1.91
-1.528
-3.727
1.331
1.227
-1.191
-1.865
-1.097
1.153
-2.833
-1.618
-3.704
3.546
4.308
1.303
-2.533
-1.773

1.405
3.184
-1.632
-3.46
1.005
1.985
-1.295
-1.74
-1.1
1.159
-2.417
-1.589
-3.384
2.846
3.26
1.118
-1.77
-1.562
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The commonly expressed proteins are involved in cell proliferation, apoptotic resistance,
or are biomarkers of chemoresistance, but it would be premature to speculate about
any potential role any play in TKI resistance. It may be worthwhile to probe PHB2’s role
in ERK1/2 signaling in TKI-resistant cells. Interestingly, we observed the upregulation of
ABCE1, an ATP-binding cassette sub-family member that is known to inhibit
endoribonuclease activity and influences mRNA turnover. ABCE1 upregulation is found
in several other cancers, and siRNA-mediated depletion of ABCE1 induces inhibits
cellular proliferation, sensitizes cancer cells to chemotherapy, and induces apoptosis in
breast, lung, and esophageal cancers[194-196]. ASNS is also upregulated in all three TKIresistant cell lines. ASNS catalyzes the conversion of arginine to asparagine, and is
known to mediate cisplatin-resistance in nasopharyngeal carcinoma, doxorubicin
resistance in uterine cancer, and is highly upregulated in melanoma and lymphoma[197200]. Further study of ASNS in TKI-resistance may be warranted. Also noteworthy is the
upregulation of DDX6 and DDX21, which are ATP-dependent RNA helicases that are
integral components of the mRNA degradation machinery. Ablation of DDX6 in
colorectal cancer cells inhibits cell proliferation and promotes apoptosis[201, 202].
DDX21 is another ATP-dependent RNA helicase that was recently uncovered to be a
crucial regulator of ribosome biogenesis, and interacts with a wide variety of RNA,
including non-coding RNAs involved in the formation of ribonucleoprotein complexes,
including ribosomal RNA, small nucleolar RNAs (snoRNAs) and 7SK RNA[203]. DDX21 is
also highly upregulated in lymphomas, breast, and colon cancer, and is known to drive
AP-1 transcription and promote rRNA processing, driving tumorigenesis in multiple
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fashions[204-206]. The upregulation of DDX6 and DDX21 may play key roles in the
imatinib, nilotinib, and dasatinib resistance in our K562-TKI resistant cell lines by
inhibiting the synthesis of proteins involved in TKI-mediated apoptosis, and partially
explain the dramatic differences observed between the transcriptome and proteome in
our K562-TKI resistant cell lines.

A comparison of the significantly differentially expressed genes between the
transcriptome and proteome of TKI-resistant K562 cells with respect to the parental
K562 cells requires less stringent differential expression requirements, as no proteins
with a log2 fold change of ±2 were detected in both our SWATH analysis and RNA-seq
analysis. We only detected one protein that displayed a significant fold change at the
mRNA level and protein level across all TKI-resistant samples as compared to the
parental K562 cell line, TPM4.

Table 11. Common genes and proteins in K562-TKI resistant cells found to have
significant (p<0.05) differential expression with respect to parental K562 cells
determined by RNA-seq and SWATH-MS. Differential expression of proteins was
analyzed using Skyline, and statistics were compiled using MSStats. Differential
expression of mRNA trancripts was analyzed using Cufflinks on the Galaxy platform. Fold
change is expressed in terms of log2.
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Cell Line
IR
NR
DR

TPM4 Transcript log2 Fold
Change
0.808
0.467
-0.698

TPM2 Protein log2 Fold
Change
-1.231
-2.533
-1.77

In both the K562-IR and K562-NR cells the transcription of TPM4 was upregulated, but
the protein levels were downregulated, and in the K562-DR cells there was significantly
more change in protein levels than mRNA levels, which simply demonstrates the
transient nature of protein stability. It is possible that the protein was never translated
from the mRNA, or the rates of protein degradation far surpassed the rates of protein
synthesis in the K562-IR and K562-NR samples. Without further experimentation, it will
be impossible to accurately explain the nature of this seemingly contradictory
observation. However, it is not particularly surprising that the levels of mRNA and
protein do not support each other, and illustrates the need to develop biomarkers of
disease progression and response to chemotherapy at the protein level, the level at
which most therapies exert their targeted action.

Transcriptomic data and proteomic data does not necessarily correlate, as there are
many levels of post-transcriptional and post-translational modifications that contribute
to protein levels at any given time. Previous studies have demonstrated a significant lack
of correlation between the transcriptome and the proteome: Ghazalpour et al found a
correlation coefficient of only 0.27 for transcript/protein expression similarity[169], Foss
et al found a mRNA-protein correlation coefficient of 0.24[168], and de Sousa Abreu R et
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al reported a mRNA-protein correlation coefficient of 0.22[207]. All of these studies
support the concept that much of the level of protein expression is post-transcriptional
and post-translational regulation. Given the significant genetic and metabolic
reprogramming necessary to evolve resistance to imatinib, nilotinib, or dasatinib, it is
unsurprising that our data reflects a low correlation between the transcriptome and
proteome.

One explanation for the low correlation between our RNA-seq and SWATH-MS data
could also be the significant difference in sensitivity between the measurement
techniques. RNA-seq is extremely sensitive, and generally detects all transcripts
regardless of their abundance. When using SWATH-MS to analyze the proteome of a
sample set, it is imperative to develop a spectral reference library with maximum
coverage of the proteome, which is typically acheived by using reverse-phase
chromatography to fractionate the samples into many fractions of the same sample,
which are then sequentially analyzed by the mass spectrometer. Without fractionation,
many peptides are eluted at the same time, and the results are heavily biased towards
only the most abundant peptides, as the instrument selects the most abundant peptides
in a given MS1 window to fractionate for MS2 detection. Fractionation allows for the
total sample to be spread out over many analytical runs, allowing detection of less
abundant peptides. Due to instrument limitations we were unable to perform
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fractionation up-front of the mass spectrometric analysis, which severely limited the
depth of coverage we were able to attain in our proteomic experiments.

3.5

Identification of Unreported Peptides in SWATH Data

Proteogenomics is an emerging field combining transcriptomics and proteomics to
expand the identification of spectra collected in a proteomics experiment to the
genome. To do this, peptides obtained from RNA-seq experiments that are not
contained in the reference database are appended to freely available protein reference
databases to create a custom database unique to the sample set that is being analyzed.
This approach is particularly useful for the study of cancer pathologies, as genetic
mutations such as the emergence of fusion genes, can yield novel peptides that are not
contained in common protein reference databases. We used a proteogenomic approach
to translate unreported sequences identified in our RNA-seq experiments into peptides
we might detect in our SWATH experiments. We first used GalaxyP to convert the
format of our raw RNA-seq data from FASTQ to FASTA, and then concatenated the
mapped reads from our Tophat2 runs to the human GRCh37 assembly reference FASTA
file, and filtered all of the repeated genomic sequences[92]. Next, we used a 3-frame
translation to convert the concatenated BED files from the previous step, into a peptide
FASTA output file containing the GRCh37 reference peptides, and the peptides unique
to our samples. Finally, we compared the 3-frame translated GRCh37 reference FASTA
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file with the RNA-seq-appended reference file to filter out all shared peptides using
BLAST-P[208]. The results are shown in Table 12 below.

Table 12. Unreported peptides identified in K562-TKI resistant cells using GalaxyP.
RNA-seq reads were appended to the GRCh37 human reference database and
converted to a peptide FASTA file, and novel peptides were filtered from the original
reference database to yield peptides present in our RNA-seq samples hat were not
reported in the GRCh37 human reference database.
Peptides Identified Using GalaxyP
ARFPQQKK
DFVSSRTVTFIQTR
LTVAPPLAEPGAGK
MLLYANMIR
NQVESEVRR
QGARGLVER
RPLSANSGIDLSK
TSSSLLGTGWAV

Gene Associated with Peptide
TRAF2
N/A
ODO2
N/A
N/A
N/A
N/A
N/A

Six of the eight peptides identified in our RNA-seq data did not map to a specific gene,
and may be false positives, or map to miRNAs or genes that have yet to be characterized.
However, we were able to match two peptides from the RNA-seq data with their
corresponding genes. The first peptide, ARFPQQKK, mapped to the gene TRAF2, which
regulates the activity of JNK and NFκB and plays a central role in cell proliferation and
apoptosis, and is an essential component of several E3-ubiquitin ligase complexes.
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Unfortunately, ARFPQQKK could not be identified in the SWATH-MS data. Conversely,
LTVAPPLAEPGAGK, a peptide corresponding to the ODO2 gene was identified in both
the RNA-seq data and the SWATH-MS data. However, the predicted lysine residue
(LTVAPPLAEPGAGK) identified in the transcript detected in the RNA-seq data actually
corresponds to a proline residue (PTVAPPLAEPGAGK)in the peptide detected in the
SWATH-MS data, which is the correct peptide according to published FASTA databases.
RNA-seq is a highly sensitive technique, and it is likely that a very small fraction of
transcripts contained this mutation, but were filtered as novel peptides despite very low
transcript levels. Despite the L-P mutation, the PTVAPPLAEPGAGK peptide was still only
identified in our database searches using the custom FASTA file derived from our RNAseq data. The identification of point mutations is an important goal of proteogenomics,
as transcriptomic data does not inform about translational errors that could potentially
be drivers of oncogenesis. By appending a data from our RNA-seq analysis with an
existing protein database we were able to identify a mutation that would have been
overlooked without the implementation of a proteogenomic approach. Future
experiments will optimize our SWATH-MS methods to increase the proteomic coverage
of our samples, and we expect that optimization of our methods will allow for
identification of novel peptides that we were unable to detect in the data presented
here.
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3.6

Conclusions

In this chapter we report the results of a proteomic analysis of the K562-IR, K562-NR,
and K562-DR cell lines with respect to the parental K562 cell line. Across all three TKIresistant cell lines we identified the upregulation of PHB2, a protein involved in cell
proliferation, inhibition of apoptosis, and ERK1/2 signaling. In the K562-IR cells we
observed a significant downregulation of eleven proteins involved in the formation of
the desmosome complex. The K562-NR cell line and K562-DR cell line shared many
common proteins differentially expressed at similar levels, namely, the significant
downregulation of BTF3L4, CAST, NUCKS1, AHNAK, ZPR1, TIMM8A, SH3BGRL, ZC3H18
and MYL6, along with the upregulation of SLC25A3, VDAC1 and VDAC2, LRRC59, and
VAPA. Finally, we used a proteogenomic approach to add novel peptides identified in
our RNA-seq experiment to generate a custom FASTA file for which to search our
SWATH-MS data against. We were able to identify a peptide corresponding to ODO2
which was not identified using the GRCh37 human reference database, demonstrating
the utility of proteogenomics in cancer research. Without utilizing a proteogenomic
approach, the finding of an unreported peptide would have been lost between the
transcriptomic and proteomic data, overlooking a potentially significant finding. The
ability to append protein databases to include peptides predicted to be present in a
sample based on RNA-seq data is a crucial crossover between transcriptomics and
proteomics, and provides a deeper understanding of potential drivers of cancer
pathology by adding a dimension of information to previously existing modes of analysis.
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CHAPTER 4.

SUMMARY AND FUTURE DIRECTIONS

The work in this thesis provides many avenues to explore potentially novel mechanisms
of imatinib, nilotinib, and dasatinib resistance in a cell-culture model of evolved
resistance using K562 cells. In chapter 2, we describe the use of RNA-seq to identify
differences in transcript expression in K562-IR, K562-NR, and K562-DR cells with respect
to the parental K562 cell line, and then distinguish transcripts that are differentially
expressed across all three TKI-resistant cell lines as compared to the parental K562 cell
line, which suggest potential avenues for future research into general mechanisms of
TKI-resistance in a CML cell-culture model. We also describe the differences in
transcriptexpression within each individual cell line, which serves to highlight the
different evolutionary pressures that an individual TKI can exert on a cell line, and how
an individual TKI can affect the acquisition of a resistant phenotype through the
alteration of differential expression of a wide variety of genes, ultimately leading to
resistance.

We identified several genes we suspected might be involved in general TKI-resistance,
AXL, ACP5, and CYP2S1. AXL had been previously demonstrated to be involved in
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imatinib and nilotinib resistance, presumably through a scaffolding function that
allowed for compensatory activation of LYN kinase[42], and the ablation of the AXL
transcript restored sensitivity to imatinib and nilotinib in resistant cell lines to a level
comparable to the parental K562 cell line, which served as an internal control to validate
our cell culture model as a clinically-relevant model of acquired TKI-resistance. However,
the K562-DR cell line did not sharply respond to AXL ablation in the same manner as the
K562-IR and K562-NR cell lines did, suggesting that the mechanisms underlying dasatinib
resistance are not AXL-dependent. It is interesting to note that AXL upregulation at the
transcript level correlates with the downregulation of many proteins involved in the
formation of the desmosome complex. The desmosome complex is integral in cell-cell
adhesion and the loss of the proteins involved in the formation of the desmosome
complex could serve as a biomarker of imatinib resistance.

The ablation of ACP5 had a similar effect on the proliferation of K562-IR and K562-NR
cells, restoring sensitivity to imatinib and nilotinib, respectively. However, the K562-DR
cells again did not have a significant response to ACP5 ablation, signifying that dasatinib
resistance is mediated through an alternative mechanism, and ACP5 upregulation may
be an artifact of another mechanism conferring resistance to dasatinib.
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The ablation of CYP2S1 in K562-IR cells dramatically increased sensitivity to imatinib, but
increased resistance to imatinib in K562 cells. This seemingly illogical result underscores
the complexity of drug-metabolism, and eliminates CYP2S1 as a serious candidate for
further study. Ablation of CYP2S1 in K562-NR cells had a similar effect, though less
pronounced. In K562-DR cells, the ablation of CYP2S1 slightly sensitized the cells to
dasatinib, although the results mirror the effects of ablating AXL and ACP5 from
previous experiments. The results of this RNA-seq study did not elucidate any promising
mechanisms of resistance to dasatinib.

One of the advantages of RNA-seq is the ability to detect minor changes in the
transcription profile between samples. We were able to detect the transcription of
genes that were not present in the parental K562 sample, or the total loss of
transcription in the TKI-resistant cell line. We identified a massive upregulation in
transcription of miRNA3940 and miRNA637, and SNORD88A and SNORD88B in K562-IR
cells, and massive upregulation of SNORD33 and SNORD35A in K562-NR cells, yet a
massive downregulation of SNORD88C in K562-NR and K562-DR cells. At this time, there
is little known about the function of any of these transcripts, but there has been several
reports that indicate miRNA’s and snORD’s play a role in translational regulation, which
may partially explain the lack of correlation between the transcriptome and proteome,
and the fact that the majority of differentially expressed proteins are downregulated.
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miRNA and snORDS may be useful information for future studies to follow up on the
emergence or disappearance of these transcripts with regards to TKI-resistance.

Finally, we described the detection of novel fusion transcripts emergent in our TKIresistant cells. Fusion genes are responsible for many disease pathologies, CML being
one of them. Detection of novel fusion genes is integral to the characterization of
disease pathology, especially in drug resistance, as the detection of these transcripts
could help predict future resistance to chemotherapy and guide therapeutic regimens
for patients.

In the third chapter, we used SWATH-MS to profile the proteomic differences between
K562 parental cells and the TKI-resistant cells we have generated in-house. The
significantly differentially expressed proteins in our K562-IR cell line alluded to the loss
of the desmosome as a biomarker of TKI-resistance, as we observed the loss of eleven
proteins composing the desmosome, a structure that mediated cell-cell adhesion, and
the loss of which is a hallmark of CML progression. K562-NR cells showed a loss of
proteins involved with the regulation of cellular metabolism, suggesting that chronic
nilotinib exposure has a role in rewiring the metabolic functions of K562 cells, conferring
resistance to nilotinib. Dasatinib-resistant K562 cells showed a very similar protein
expression profile to K562-NR cells, as many of the proteins differentially expressed play
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some role in metabolism. Overall, eighteen proteins were commonly differentially
expressed at a log2 fold change of ±1 between the three TKI-resistant cells, including
PHB2, CAST, NUCKS1, DDX6, and DDX21. PHBS was significantly unregulated, and has
been shown to be involved in apoptosis resistance, cell-cycle checkpoint release, and
ERK1/2 signaling. CAST and NUCKS1 are known biomarkers of oncogenesis in many
other cancers, so it may be worth tracking their protein expression in chemoresistant
cells as biomarkers of TKI-resistance in CML. We also identified the upregulation of
DDX6 and DDX21, proteins involved in translation of mRNA, which could partially
explain the lack of correlation between the transcriptomic and proteomic data.

Lastly, we used a proteogenomic approach to identify novel peptides in TKI-resistant
cells. We were able to identify one novel mutant peptide, corresponding to the ODO2
gene that was not represented in the canonical GRCh37 FASTA database, and contained
a lysine-proline mutation from the mRNA to protein level. The ability to add a layer of
information blending transcriptomic and proteomic data is critical to understanding
complex pathological phenotypes, and this data demonstrates the power of the
proteogenomic approach in cancer research.

Optimization of SWATH-MS methods will certainly increase the coverage of protein
identification, and up-front fractionation of the samples will improve base protein

99

identification. The results of the data reported in this thesis suggest several promising
therapeutic avenues to explore, but there is room to improve. First and foremost, the
SWATH-MS methodology needs to be optimized, specifically the need for up-front
fractionation and a longer HPLC gradient. These factors will certainly improve the
identification of proteins, and allow a more accurate comparison of our results to our
RNA-seq data. It is clear that there is little correlation between the transcriptome and
proteome of our K562-TKI resistant cells, and protein levels in a cell do not yield any
information about the activity of those proteins. Moving forward, a major effort will be
made to understand the post-translational modifications that dictate the activity of the
signaling proteins in our K562-TKI resistant cells. By enriching for phospho-peptides we
will be able to construct a map of the signaling events underlying chemoresistance in
our model of acquired TKI-resistance, which will be more informative than the
transcriptome or proteome alone.

The goal of this research is to identify biomarkers of resistance and propose novel
resistance mechanisms, and the best way to understand the dynamics of how a cell
responds to a stimulus is by integrating multiple layers of information to determine
which genes are transcribed, which proteins are translated, and how post-translational
modification of proteins effect the molecular signaling pathways underlying TKIresistance. In this thesis we have described the transcriptional and translational levels;
the next step in elucidating the mechanisms of chemoresistance must be a
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comprehensive characterization of the phospho-proteome in our model cell lines. The
findings of our research must then be compared to human patient samples to validate
our findings. The findings of this thesis have shined a light on many paths leading to the
acquisition of chemoresistance. As Rosalia de Castro once said, “We can see the path,
but we don’t know where it leads. Not knowing where it leads is what inspires us to
travel it.”
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